

IN THE UNITED STATES DISTRICT COURT
FOR THE MIDDLE DISTRICT OF NORTH CAROLINA

NATERA, INC.,)
)
Plaintiff,)
) 1:23-CV-629
v.)
)
NEOGENOMICS)
LABORATORIES, INC.,)
)
Defendant.)

ORDER

Natera, Inc. and NeoGenomics Laboratories, Inc. are research-focused healthcare companies that operate in the oncology testing industry. Both companies have products that can be used for earlier detection of cancer relapse. Natera seeks a preliminary injunction, contending that NeoGenomics' product, RaDaR, infringes two of Natera's patents. Because Natera has shown a likelihood of success on the merits that NeoGenomics is infringing the '035 patent and the other requirements for injunctive relief are met, the motion will be granted.

For purposes of this Order, the Court makes the following findings of fact and conclusions of law.

I. FACTS

As relevant here, Natera holds two method patents. Patent No. 11,519,035 issued on December 6, 2022, Doc. 1-2 at 2, and Patent No. 11,530,454 issued on December 20, 2022. Doc. 1-1 at 2. In simplified terms, the '035 patent provides methods and compositions for amplifying targeted genetic material while reducing amplification of

non-targeted genetic material. *See* Doc. 1-2 at 2, 89. The ‘454 patent provides methods, systems, and computer readable medium for detecting variations in genetic material indicative of disease or disease recurrence. *See* Doc. 1-1 at 2, 137.

Natera uses the methods described in these two patents in a product marketed under the brand name Signatera. *See* Doc. 9-18 at 2–3.¹ NeoGenomics offers a competing product under the brand name RaDaR. Doc. 94 at ¶ 10. RaDaR has been used in clinical cancer research since April 2020.² *Id.* at ¶ 11. It has been commercially available since March 2023. *Id.* at ¶ 15.

Signatera and RaDaR each work by identifying circulating DNA fragments from cancer cells within the bloodstream. *See* Doc. 13 at ¶ 125; Doc. 94 at ¶ 10. The presence of these tumor DNA fragments can indicate the efficacy of cancer treatment and the risk of cancer recurrence. Doc. 7 at ¶ 23; Doc. 13 at ¶ 34.

During a cell’s life cycle, it naturally sheds short fragments of DNA into the bloodstream. Doc. 13 at ¶ 36. These DNA fragments are referred to as cell-free DNA (cfDNA). *Id.*; Doc. 97 at ¶ 43. Both healthy cells and cancerous cells create cfDNA. Doc. 13 at ¶ 36. The subset of cfDNA that comes from cancer cells is referred to as circulating tumor DNA (ctDNA). *Id.*; Doc. 97 at ¶ 247.

¹ Throughout this Order, the Court has cited some of the evidence in the record that supports its factual findings but has made no attempt to cite all the evidence supporting its findings.

² RaDaR was initially offered by a company known as Inivata. Doc. 94 at ¶ 11. NeoGenomics acquired Inivata in 2021. *Id.* at ¶ 12.

If a patient has a positive response to cancer treatment, the patient's tumor typically decreases in size, eventually becoming undetectable in radiographic imaging or clinical examination. Doc 13 at ¶ 34. If tumor cells remain in a patient's body after treatment, there is the potential for cancer relapse, either locally or through metastases. *Id.* Molecular residual disease (MRD) refers to the presence of small amounts of tumor DNA molecules in the body after treatment. *Id.*; Doc. 7-38 at 2. Early detection of MRD supports better patient outcomes. Doc. 13 at ¶ 34.

MRD tests are either tumor informed or tumor naïve. Doc. 7 at ¶ 24. Tumor informed tests are designed from a patient's genetic information obtained from a tissue biopsy of the patient's tumor. *Id.* These bespoke tests are often preferred by doctors and are seen as highly sensitive because they are personalized to the patient. *Id.* at ¶¶ 34–35; Doc. 92-1 at 4, 17. Tumor naïve tests can provide faster results but are less favored by doctors because they are perceived to be less accurate. Doc. 7 at ¶¶ 34–35.

Signatera, Natera's product, and RaDaR, NeoGenomics' product, are tumor informed MRD tests that work by detecting trace amounts of ctDNA in a patient's bloodstream. *See* Doc. 13 at ¶¶ 115, 125; Doc. 94 at ¶ 10. Patients known to have cancer first provide tumor tissue samples. Doc. 13 at ¶ 118; Doc. 94 at ¶ 10. Next, the DNA from those tissue samples is sequenced, and the DNA information is used to design liquid biopsy MRD assays. Doc. 13 at ¶¶ 118–19; Doc. 94 at ¶¶ 9–10. After cancer treatment ends, patients regularly provide blood samples for testing. Doc. 13 at ¶ 120; Doc. 94 at ¶ 10. Using tumor informed MRD assays, doctors and scientists can detect DNA from cancer cells in the blood in the form of ctDNA. Doc. 13 at ¶¶ 120–22; Doc. 94 at ¶ 10.

Natera is the leader in the MRD assay market. *See* Doc. 7 at ¶¶ 45, 73; Doc. 92-1 at 2; Doc. 11-9 at 42. According to one report, Natera has 74% of the total market share for both tumor informed and tumor naïve tests. Doc. 92-1 at 12, 17. RaDaR is the only other tumor informed MRD test available for clinical use and covered by private insurance.³ *See* Doc. 7 at ¶ 48. Other companies, such as Guardant Health, compete in the MRD space, but they offer tumor naïve products, not tumor informed products. *See id.* at ¶ 53; Doc. 92-1 at 17. The MRD testing market is expected to grow substantially over the next few years. Doc. 92-1 at 3–4.

Additional findings of fact will be stated as they become relevant.

II. PRELIMINARY INJUNCTION STANDARD

Courts have the power to grant preliminary injunctions in patent infringement lawsuits. *See High Tech Med. Instrumentation, Inc. v. New Image Indus. Inc.*, 49 F.3d 1551, 1554 (Fed. Cir. 1995); 35 U.S.C. § 283. To establish a preliminary injunction is warranted, the patentee seeking an injunction must show: “(1) it is likely to succeed on the merits, (2) it is likely to suffer irreparable harm in the absence of preliminary relief, (3) the balance of equities tips in its favor, and (4) an injunction is in the public interest.” *BlephEx, LLC v. Myco Indus., Inc.*, 24 F.4th 1391, 1398 (Fed. Cir. 2022) (quoting *Winter v. Nat. Res. Def. Council, Inc.*, 555 U.S. 7, 20 (2008)) (cleaned up).

³ Until recently, Invitae offered another tumor informed MRD test under the brand name PCM. After a jury in the District of Delaware found that product infringed other patents held by Natera, the court permanently enjoined Invitae from offering PCM for clinical use. *See* Doc. 164-1 (redacted permanent injunction entered in *Natera, Inc. v. ArcherDX, Inc.*, No. 20-CV-125 (D. Del. Nov. 21, 2023)).

III. SUCCESS ON THE MERITS

To show a likelihood of success on the merits, the moving party must demonstrate “(1) it will likely prove infringement and (2) its infringement claim will likely withstand challenges to the validity and enforceability of the patents.” *See Purdue Pharma L.P. v. Boehringer Ingelheim GMBH*, 237 F.3d 1359, 1363 (Fed. Cir. 2001) (cleaned up). In patent cases, the likelihood of success factor is governed by Federal Circuit law. *See ABC Corp. I v. P’ship and Unincorporated Ass’ns Identified on Schedule “A”*, 52 F.4th 934, 941 (Fed. Cir. 2022). When evaluating the likelihood of success, courts consider all the burdens and presumptions that would apply at trial. *See Purdue*, 237 F.3d at 1363.

To assess the likelihood of infringement, courts first “determine the scope and meaning of the patent claims asserted.” *Oakley, Inc. v. Sunglass Hut. Int’l*, 316 F.3d 1331, 1339 (Fed. Cir. 2003) (cleaned up); *see also CommScope Techs. LLC v. Dali Wireless Inc.*, 10 F.4th 1289, 1295 (Fed. Cir. 2021). Then “the properly construed claims are compared to the allegedly infringing device.” *Oakley*, 316 F.3d at 1339 (cleaned up). Infringement claims must also withstand any challenges to a patent’s validity and enforceability. *See Purdue*, 237 F.3d at 1363.

IV. ‘035 PATENT – LIKELIHOOD OF SUCCESS ON THE MERITS

A. Infringement

For purposes of the preliminary injunction motion, Natera asserts that the RaDaR product offered by NeoGenomics infringes claims 1, 12, and 13 of the ‘035 patent. Doc. 71-4 at 2. Claim 1 states:

A method for amplifying and sequencing DNA, comprising:
tagging isolated cell free DNA with one or more universal tail adaptors to generate tagged products, wherein the isolated cell-free DNA is isolated from a blood sample collected from a subject who is not a pregnant woman;
amplifying the tagged products one or more times to generate final amplification products, wherein one of the amplification steps comprises targeted amplification of a plurality of single nucleotide polymorphism (SNP) loci in a single reaction volume, wherein one of the amplifying steps introduces a barcode and one or more sequencing tags; and
sequencing the plurality of SNP loci on the cell free DNA by conducting massively parallel sequencing on the final amplification products, wherein the plurality of SNP loci comprises 25–2,000 loci associated with cancer.

Doc. 1-2 at 213. Amplification refers to increasing “the number of copies of a molecule, such as a molecule of DNA.” *Id.* at 109.

Natera has made a strong showing that the RaDaR test made and sold by NeoGenomics uses the method claimed in the ‘035 patent and infringes the ‘035 patent. It is likely to succeed on the merits of its infringement claim.

NeoGenomics contends that the claims at issue require targeted amplification of already tagged DNA and that RaDaR does not use targeted amplification on tagged products. *See* Doc. 89 at 11–12; Doc. 97 at ¶¶ 89–93. But this ignores the fact that RaDaR first tags the products with the CS1 adaptor sequence, then performs targeted amplification to tag the products a second time with the CS2 sequence. *See* Doc. 13 at ¶¶ 44, 88 (explaining RaDaR uses teachings of Forshew); Doc. 145-1 at 57, 60 (discussing PCR amplification and CS1 and CS2 tagging in Forshew). Thus, RaDaR amplifies “the tagged products one or more times to generate final amplification products, wherein one of the amplification steps comprises targeted amplification.” Doc.

1-2 at 213. Natera has shown a likelihood of success on the merits on its claim that NeoGenomics infringes Claim 1 of the '035 patent.

NeoGenomics also contends that the dependent Claims 12 and 13 require that the tagging referenced in Claim 1 occur over two rounds of polymerase chain reaction (PCR)⁴ because Claims 12 and 13 refer to a first primer comprising a first universal tail adaptor and a second primer comprising a second universal tail adaptor. *See* Doc. 89 at 12; Doc. 1-2 at 213. But an independent claim like Claim 1 is “broader than the claims that depend from it,” *Littlefuse, Inc. v. Mersen USA EP Corp.*, 29 F.4th 1376, 1380 (Fed. Cir. 2022), and “each claim in a patent is presumptively different in scope.” *Trs. of Columbia Univ. in N.Y. v. Symantec Corp.*, 811 F.3d 1359, 1370 (Fed. Cir. 2016).

When a limitation found in a dependent claim is the only meaningful difference between the dependent and independent claim, “the independent claim is not restricted by the added limitation in the dependent claim.” *Id.*; *see also Acumed LLC v. Stryker Corp.*, 483 F.3d 800, 806 (Fed. Cir. 2007) (holding that proposed claim readings should not make the independent and dependent claims identical in scope). This argument does not weaken Natera’s likelihood of success on the merits as to infringement of Claim 1.

B. Validity

To show a likelihood of success, the patent holder must demonstrate a patent is likely to withstand any challenges to validity. *See Purdue*, 237 F.3d at 1363. A patent is presumed valid. *Id.* at 1365; *KSR Int’l Co. v. Teleflex, Inc.*, 550 U.S. 398, 412 (2007).

⁴ PCR is a common method of amplification. *See* Doc. 141-6 at 7.

The party challenging the validity of a patent must come forward with evidence that raises a substantial question of validity. *Titan Tire Corp. v. Case New Holland, Inc.*, 566 F.3d 1372, 1376 (Fed. Cir. 2009). The patentee then has the “burden of responding with contrary evidence.” *Id.* at 1377. If the patentee does not prove the validity question “lacks substantial merit,” courts will deny the motion for a preliminary injunction. *Amazon.com, Inc. v. Barnesandnoble.com, Inc.*, 239 F.3d 1343, 1350–51 (Fed. Cir. 2001).

NeoGenomics challenges the validity of the ‘035 patent on several grounds, primarily contending that it is obvious. *See* Doc. 89 at 15–16. NeoGenomics also makes shorthand or conclusory arguments that there are issues with the patent’s written description, that Natera did not properly explain changes made to the named inventors, and that the ‘035 patent covers patent-ineligible subject matter. *See id.* at 16–17, 19.

1. Obviousness

A patent cannot issue when “the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious . . . to a person having ordinary skill in the art.” 35 U.S.C. § 103; *see also Teleflex*, 550 U.S. at 406–07. A party seeking to show a patent is invalid on obviousness grounds must show that “a person of ordinary skill in the art would have been motivated to combine or modify the teachings in the prior art and would have had a reasonable expectation of success in doing so.” *Regents of Univ. of Cal. v. Broad. Inst.*, 903 F.3d 1286, 1291 (Fed. Cir. 2018).

An invention is not automatically obvious just because a motivation to combine may exist, *see Arctic Cat Inc. v. Bombardier Recreational Prods. Inc.*, 876 F.3d 1350,

1359–60 (Fed. Cir. 2017), or “because all of the claimed limitations were known in the prior art at the time of the invention.” *Forest Lab ’ys, LLC v. Sigmapharm Lab ’ys, LLC*, 918 F.3d 928, 934 (Fed. Cir. 2019). A challenger asserting obviousness must give “some articulated reasoning with some rational underpinning to support the legal conclusion of obviousness.” *In re Kahn*, 441 F.3d 977, 988 (Fed. Cir. 2006). Mere conclusory statements tend to show hindsight bias, not that the invention is obvious. *ActiveVideo Networks, Inc. v. Verizon Commc ’ns, Inc.*, 694 F.3d 1312, 1327 (Fed. Cir. 2012).

The priority date for the claims of the ‘035 patent is May 18, 2011, *see* Doc. 1-2 at 2; Doc. 138-2 at 7–8, so the prior art must be from before this date. NeoGenomics first asserts that the Fluidigm Access Array System, discussed in the 2010 Kaper publication renders the ‘035 patent obvious. *See* Doc. 89 at 15–16; Doc. 97-14 (abstract); Doc. 97-15 (poster). But Dr. Kaper used DNA samples from tumor tissue, not cfDNA, in discussing Access Array. *See* Doc. 141 at ¶ 156.

NeoGenomics contends that it would have been obvious to modify Access Array for cfDNA because cfDNA was known at this time to be useful for cancer detection. *See* Doc. 89 at 15; Doc. 97 at ¶¶ 240–41. But there were many well-known barriers to using cfDNA. *See* Doc. 141 at ¶ 157 (Tumor tissue samples provide tumor-associated DNA in greater quantity than the ctDNA found in cfDNA.); Doc. 141-2 at 2 (Cell-free DNA is fragmented and exists in low yield within the body.); Doc. 13-7 at 2 (Circulating tumor DNA is just a subset of cfDNA and exists in even lower yields.); Doc 141 at ¶ 16 (Even if a cfDNA molecule has a SNP of interest, the cfDNA may be fragmented such that it “does not contain sites for both primers of a primer pair to bind” and the SNP will not

amplify “successfully when PCR is performed.”). These challenges associated with cfDNA, and others, presented obstacles to successfully amplifying and sequencing ctDNA with precision during the relevant time period, *see* Doc. 141-2 (published October 2016); Doc. 141 at ¶¶ 19–21, making it unlikely a person skilled in the art would have been motivated to use cfDNA with Access Array and would have anticipated success in doing so. *See Forest Lab ’ys*, 918 F.3d at 934; *Arctic Cat*, 876 F.3d at 1359–60.⁵

NeoGenomics’ assertions about Access Array appear to show hindsight bias more than they support a substantial question of obviousness. *ActiveVideo*, 694 F.3d at 1327.

In passing, NeoGenomics also contends that something called “ARM-PCR” renders the ‘035 patent obvious for “similar reasons.” Doc. 89 at 15. This conclusory assertion does not raise a substantial question of validity.⁶

2. Written Description

Title 35 U.S.C. § 112 requires a patent specification to contain a written description of the invention that “discloses and teaches” what is claimed. *Ariad Pharms., Inc. v. Eli Lilly and Co.*, 598 F.3d 1336, 1347 (Fed. Cir. 2010); 35 U.S.C. § 112(a). There is no required “particular form of disclosure,” and the written description need not use the

⁵ At oral argument, Natera’s counsel said that Natera had also invented ways to overcome these barriers.

⁶ In support of this half-a-sentence argument, NeoGenomics provides a bulk citation to some 68 paragraphs covering well over 10 pages in a declaration from one of its experts, *see* Doc. 89 at 15, citing Doc. 97 at ¶¶ 235–303. Expert declarations are not substitutes for briefs and implicit attempts to incorporate them by reference cannot be used to avoid the word limits for briefing. *See* discussion *infra* at 13.

exact words of the claims. *See Ariad*, 598 F.3d at 1352; *Univ. of Rochester v. G.D. Searle & Co., Inc.*, 358 F.3d 916, 922–23 (Fed. Cir. 2004).

NeoGenomics contends that the specification for the ‘035 patent “lack[s] examples of the claimed processes” and “[t]he claims are disassociated from the described invention.” *See* Doc. 89 at 17. This argument, made in one paragraph, does not raise a substantial question of validity.⁷

3. Inventorship

The named inventors in an issued patent are presumed correct. *Eli Lilly and Co. v. Aradigm Corp.*, 376 F.3d 1352, 1358 (Fed. Cir. 2004). A “party seeking correction of inventorship must show by clear and convincing evidence that a joint inventor should have been listed.” *Blue Gentian, LLC v. Tristar Prods., Inc.*, 70 F.4th 1351, 1357 (Fed. Cir. 2023) (citing *Aradigm*, 376 F.3d at 1358). While a patent must reflect true inventorship, “a patent cannot be invalidated if inventorship can be corrected instead.” *Egenera, Inc. v. Cisco Sys., Inc.*, 972 F.3d 1367, 1376 (Fed. Cir. 2020).

Correcting inventorship for an issued patent can be done either by petition to the Director of the U.S. Patent and Trademark Office or by court order. *See* 35 U.S.C.

⁷ In support of its perfunctory “disassociation” argument, Natera again provides a bulk citation to over 20 paragraphs of an expert’s declaration. *See* Doc. 89 at 17, citing Doc. 97 at ¶¶ 404–26. But most of those paragraphs are addressed to the ‘454 patent, and such bulk citations do not direct the Court’s attention with any specificity to facts relevant to the ‘035 patent. *See* Doc. 27 at ¶ 1 (Order requiring that citations to a multi-page exhibit “must contain a pin cite to the specific page” or “paragraph number”). The Court is not required to sift through blocks of evidence itself to locate the truffles. *See Hughes v. B/E Aerospace, Inc.*, No. 12-CV-717, 2014 WL 906220, at *1 n.1 (M.D.N.C. Mar. 7, 2014) (“A party should not expect a court to do the work that it elected not to do.”). As the Court has stated, *see supra* note 6, at 10 and discussion *infra* at 13, expert declarations are not mechanisms to avoid word limits.

§§ 256(a), (b). Inventorship in a patent application can also be corrected, 35 U.S.C. § 116(c), and the patent office does not require an explanation for the correction. *See* 37 C.F.R. § 1.48 (setting out requirements for correction of inventorship in provisional and nonprovisional patent applications).

NeoGenomics does not show by clear and convincing evidence that an inventor is missing from the '035 patent. *See Blue Gentian*, 70 F.4th at 1357. In fact, NeoGenomics does not raise any issues with any specific inventor of the '035 patent, saying only that the changes Natera made during the patent application process “appear dubious.” *See* Doc. 89 at 19. This perfunctory assertion does not raise a substantial question of invalidity for the '035 patent based on inventorship.

4. Patent Ineligible Subject Matter

In arguing that the '035 patent is not valid because of ineligible subject matter, NeoGenomics purports to incorporate by reference an argument made in another brief. Doc. 89 at 19 (referencing NeoGenomics' motion to dismiss brief, Doc. 52). The Court will disregard this argument for purposes of this motion.

The Local Rules limit briefs in support of motions and responsive briefs to no more than 6,250 words. *See* LR 7.3(d). Per this Court's standard order, when a party incorporates arguments made in other briefs, the incorporating brief's word count is “correspondingly decreased.” Doc. 27 at ¶ 1. The word count in the incorporated brief, Doc. 52, is some 6,233 words. The word count in the incorporating brief, Doc. 89, excluding the incorporated argument, is some 6,218 words. NeoGenomics has thus attempted to surpass the word limit by thousands of words.

Word or page limits are common across courts of all stripes for obvious reasons; among other things, such limits require parties to avoid rhetoric and to present their best arguments, and they facilitate prompt, efficient resolution of cases. Efforts to circumvent word limits by incorporating briefs by reference or dividing one motion into several motions are improper. *See, e.g., Basulto v. Netflix, Inc.*, No. 22-CV-21796, 2022 WL 17532279, at *2 (S.D. Fla. Dec. 8, 2022) (collecting cases); *Monec Holding AG v. Motorola Mobility, Inc.*, No. 11-CV-798, 2014 WL 4402825, at *2 (D. Del. Sept. 5, 2014) (finding opposing party prejudiced if forced to respond to legal arguments in incorporated exhibit); *Aircraft Tech. Publishers v. Avantext, Inc.*, No. 7-CV-4154, 2009 WL 3833573, *1 (N.D. Cal. Nov. 16, 2009) (striking summary judgment motions that were improperly filed separately to avoid page limits).

At the preliminary injunction hearing,⁸ NeoGenomics focused on the arguments it made in its preliminary injunction opposition brief, not the incorporated brief about patent ineligible subject matter. The Court declines to consider the subject matter arguments in connection with the preliminary injunction motion.

C. Conclusion

Natera has demonstrated a likelihood of success on the merits for its '035 patent infringement claim. RaDaR likely infringes Claim 1 of the '035 patent, and NeoGenomics has not raised a substantial question of validity.

⁸ At the Court's request, the deputy clerk had advised the parties several days before the hearing of a number of matters the Court wanted addressed, one of which was the effort to avoid the word limits by incorporating another brief.

V. '454 PATENT – LIKELIHOOD OF SUCCESS ON THE MERITS

In view of its findings and conclusions on the '035 patent, the Court need not address whether Natera has shown a likelihood of success on its claim that the '454 patent is valid and infringed.

VI. IRREPARABLE HARM

A. Likelihood of Irreparable Harm

The plaintiff seeking preliminary injunctive relief must show a likelihood of irreparable harm. *BlephEx*, 24 F.4th at 1398. A patentee suffers irreparable harm when “forced to compete against products that incorporate and infringe its own patented inventions.” *Douglas Dynamics, LLC v. Buyers Prods. Co.*, 717 F.3d 1336, 1345 (Fed. Cir. 2013). Natera will likely suffer irreparable harm if NeoGenomics continues to offer RaDaR in the marketplace.

Evidence of head-to-head competition, lost market share, lost sales, and a decline in reputation and brand distinction can support a showing of irreparable harm. *See TEK Glob., S.R.L. v. Sealant Sys. Int'l, Inc.*, 920 F.3d 777, 793 (Fed. Cir. 2019); *Douglas Dynamics*, 717 F.3d at 1344. When two competitors directly compete “for the same customers in the same markets,” irreparable harm is evident. *See Presidio Components Inc. v. Am. Tech. Ceramics Corp.*, 702 F.3d 1351, 1363 (Fed. Cir. 2012).

Natera and NeoGenomics are direct competitors in the tumor informed MRD marketplace. *See* Doc. 7 at ¶ 131; Doc. 92-1 at 26. Indeed, NeoGenomics is Natera’s only competitor in this market. *See supra* note 3, at 4. Analysts believe NeoGenomics’ RaDaR will see significant growth in the industry. Doc. 92-1 at 5, 20. For many of

NeoGenomics' sales, Natera will lose out on potential customers, profits, business relationships, and clinical opportunities. *See Douglas Dynamics*, 717 F.3d at 1345 (holding infringer's increase in market share more relevant than patentee's ability to maintain market share).

In this industry, biopharmaceutical partnerships are important. Doc. 7 at ¶¶ 103–04. By participating in clinical trials, companies can generate product data, gain credibility in the marketplace, and contribute to published research. *Id.* at ¶¶ 79, 103. Data from clinical trials also creates the support needed for insurance coverage determinations and entry into the larger clinical marketplace. *Id.* at ¶¶ 77, 103. If forced to compete against RaDaR for participation in future clinical studies, Natera could lose out on partnerships that substantially impact Signatera's future success, a loss that is challenging to quantify. *Id.* at ¶ 105; *see also Metalcraft of Mayville, Inc. v. The Toro Co.*, 848 F.3d 1358, 1368 (Fed. Cir. 2017) (holding that “[w]here the injury cannot be quantified” and “no amount of money damages is calculable,” the harm is irreparable).

Natera has a first mover advantage as a pioneer in the tumor informed MRD market. Doc. 7 at ¶ 134. This advantage includes a period of exclusivity, in which Natera can establish brand recognition, customer loyalty, and business foundations. *Id.* at ¶ 136. Natera has never licensed the '035 patent, Doc. 14 at ¶ 16, and it has a right to exclusivity as the patent holder. *See Douglas Dynamics*, 717 F.3d at 1345; *Presidio*, 702 F.3d at 1363 (finding unwillingness to license supported irreparable injury). Natera's position as first mover will be unfairly cut short if RaDaR remains on the market.

NeoGenomics contends that the larger MRD market is the relevant market, and that Guardant Health is a bigger competitor for Natera than NeoGenomics. Doc. 89 at 23–24. While Guardant Health does operate in the MRD testing space, Doc. 92-1 at 26, it offers a tumor naïve product. *See* Doc. 7 at ¶ 53. Market analysts have confirmed that tumor informed tests are preferred by oncologists, Doc. 92-1 at 4, 17, making it highly likely that for many oncologists, the only two products are Natera’s test and NeoGenomics’ likely infringing test.

Even viewed as part of the larger MRD market, there is still irreparable harm. As the Federal Circuit has noted, “the existence of a two-player market” supports the granting of an injunction “because it creates an inference that an infringing sale amounts to a lost sale for the patentee,” but “the converse is not automatically true.” *Robert Bosch LLC v. Pylon Mfg. Corp.*, 659 F.3d 1142, 1151 (Fed. Cir. 2011) (cleaned up).

NeoGenomics contends that Natera has not shown that it has lost any contracts to NeoGenomics. But Natera has shown Moderna used RaDaR in at least one clinical study, Doc. 14-7 at 2, 11, and that NeoGenomics’ representatives are promoting RaDaR to Natera’s customers. Doc. 18-6. There is not abundant evidence of lost sales, but RaDaR is relatively new to the market; it has only been commercially available since March, Doc. 14-4, and it only received approval for Medicare coverage for use with certain specified cancers in July. Doc. 1-30. Competition and potential lost sales from RaDaR are likely to occur and cause harm.

Finally, NeoGenomics contends that Natera unreasonably delayed in filing this action. *See* Doc. 89 at 20–22. Natera received this patent in December 2022, Doc. 1-2 at

2, NeoGenomics entered the clinical market in March 2023, Doc. 14-4, and this lawsuit was filed in July 2023. Doc. 1. In the interim, Natera was already involved in ongoing patent infringement litigation over related patents. *See ArcherDX, Inc.*, No. 20-CV-125.

This is not undue delay. A patentee is not required to “sue all infringers at once” and suing four months after an infringer enters the market is relatively quick. *Robert Bosch*, 659 F.3d at 1151. Moreover, “picking off one infringer at a time is not inconsistent with being irreparably harmed.” *Id.* (citing *Pfizer, Inc. v. Teva Pharms. USA, Inc.*, 429 F.3d 1364, 1381 (Fed. Cir. 2005)).

Natera has shown a likelihood of irreparable harm.

B. Causal Nexus

In addition to likely irreparable harm, the patentee must also demonstrate “that a sufficiently strong causal nexus relates the alleged harm to the alleged infringement.” *Bio-Rad Lab’ys, Inc. v. 10X Genomics, Inc.*, 967 F.3d 1353, 1377–78 (Fed. Cir. 2020) (cleaned up); *Apple Inc. v. Samsung Elecs. Co., Ltd.*, 809 F.3d 633, 640 (Fed. Cir. 2015). While the infringing feature does not have to be the sole reason a product is bought, *Apple*, 809 F.3d at 641–42, a causal nexus exists if “the infringing feature drives consumer demand for the accused product.” *TEK Glob.*, 920 F.3d at 792 (quoting *Apple Inc. v. Samsung Elecs. Co.*, 695 F.3d 1370, 1375–76 (Fed. Cir. 2012)).

There is a causal nexus between the likely infringement and harm. It appears highly likely that NeoGenomics’ predecessor built RaDaR using the methods of the ‘035 patent as a foundation. As previously discussed *supra*, the likely infringement allows NeoGenomics to offer RaDaR as a tumor informed MRD assay, doctors who order these

tests often prefer tumor informed tests, and RaDaR's ability to perform tumor informed testing is what drives consumer demand for it.

C. BALANCE OF EQUITIES

The third factor requires the patentee show that “the balance of equities tips in its favor.” *BlephEx*, 24 F.4th at 1398. When balancing equities, the court “weigh[s] the harm to the moving party if the injunction is not granted against the harm to the non-moving party if the injunction is granted.” *Metalcraft*, 848 F.3d at 1369 (citing *Hybritech Inc. v. Abbott Lab 'ys*, 849 F.2d 1446, 1457 (Fed. Cir. 1988)). The court “may consider the parties' sizes, products, and revenue sources” in its analysis, but the “expenses incurred in creating the infringing products and the consequences of its infringement are irrelevant.” *Bio-Rad Lab 'ys*, 967 F.3d at 1378 (cleaned up).

The balance of equities weighs in favor of granting a preliminary injunction. A 2020 analyst report identified Signatera as Natera's “most valuable offering.” Doc. 7 at ¶ 158. In 2023, that same firm predicted that advances related to Signatera were key to Natera's future success. *See* Doc. 7-18 at 4 (section titled “Key catalysts for Natera's stock from here”).

A May 2023 report predicts revenue from Signatera will increase from \$130.4 million in 2022 to \$432.4 million in 2025 and make up 52.1% of Natera's total growth in revenue. Doc. 7 at ¶¶ 156–57; Doc. 7-18 at 6. In the first quarter of 2023, the “vast majority” of Natera's revenue attributable to oncology products came from “clinical Signatera volume growth.” Doc. 7-18 at 4 (section titled “More on Signatera in greater detail”). Signatera is important to Natera's economic success.

In contrast, NeoGenomics is not as dependent on RaDaR's success. It has "the broadest cancer diagnostic testing menu in the U.S.," with over 600 tests related to cancer diagnostics; NeoGenomics launches roughly 60 to 70 new test products each year. Doc. 7-19 at 3 (April 2023 report, section titled "Investment Thesis").

RaDaR also only recently became commercially available. *See* Doc. 14-4. Although NeoGenomics spent a significant amount of money acquiring Inivata and the RaDaR test, this expense does not tip the balance of equities in favor of NeoGenomics. *See Bio-Rad Lab 'ys*, 967 F.3d at 1378.

The harm to Natera if a preliminary injunction is not granted outweighs the harm to NeoGenomics in granting the injunction. *See Metalcraft*, 848 F.3d at 1369. Signatera has been on the market longer and is predicted to be a major contributor to Natera's future success. In comparison, RaDaR is relatively new to the market and is not a major product in NeoGenomics' portfolio. Natera's projected revenue streams and dependence on Signatera tips the balance of equities in favor of granting the preliminary injunction. *See Bio-Rad Lab 'ys*, 967 F.3d at 1378.

D. PUBLIC INTEREST

It is in the public's interest to uphold patent rights. *See i4i Ltd. P'ship v. Microsoft Corp.*, 598 F.3d 831, 863 (Fed. Cir. 2010); *Douglas Dynamics*, 717 F.3d at 1346 (stating the public has a "general interest in the judicial protection of property rights in inventive technology"). Before granting an injunction, courts must balance "protecting the patentee's rights" with any adverse effects on the public. *i4i*, 598 F.3d at 863; *see also Metalcraft*, 848 F.3d at 1369 ("[T]he district court should focus on whether a critical

public interest would be injured by the grant of injunctive relief.”). To reduce any adverse effects on the public interest, an injunction can be crafted to exclude current users of the enjoined product. *See i4i*, 598 F.3d at 863.

The public interest in enforcing patent rights tips in favor of granting a preliminary injunction. Anyone in need of a tumor informed MRD test will be able to get one from Natera; Signatera is clinically validated for use with the same cancers as RaDaR. *See* Doc. 10-39 at 2–3 (RaDaR cancer coverage); Doc. 10-5 at 2 (Signatera’s Medicare coverage); Doc. 10-15 at 13 (listing Signatera’s published indications as of 2022). Natera has the capacity to take on more customers. *See, e.g.*, Doc. 10-13 at 7 (Form 10-K for 2021 discussing Natera’s “global network of over 100 laboratory and distribution partners”); Doc. 10-17 at 17 (2022 presentation discussing Natera’s ability to scale up); Doc. 14 at ¶ 14; *see also* Doc. 7 at ¶¶ 89–92. The injunction can be crafted in a way that does not disrupt clinical trials and ongoing research and so that current patients can continue to use RaDaR. *See* discussion *infra*.

Consumer choice is important, as NeoGenomics points out. Doc. 89 at 30–31. But competition from an infringing product does not benefit the public, and it impedes innovation. *See Douglas Dynamics*, 717 F.3d at 1346 (so holding after verdict in favor of patent holder). While this is not a final decision on the merits, Natera has made a strong case for infringement and validity of the ‘035 patent. The need to protect consumer choice does not weigh heavily in favor of denying an injunction, in light of other evidence. *See Shure, Inc. v. ClearOne, Inc.*, No. 17-CV-3078, 2019 WL 3555098, at *25 (N.D. Ill. Aug. 5, 2019).

As NeoGenomics points out, there are patients currently using RaDaR who would be harmed if it were withdrawn from the market, and there are clinical trials and research projects, which depend on the use of RaDaR, in process or approved to begin. *See* Doc. 89 at 31. The public interest does not support enjoining these uses, despite the potential for infringement.


The public generally benefits from clinical trials, which should be carried out if they have been approved and completed if they are in process. The same is true for research projects already in process. And, as Natera recognizes, current patients using RaDaR, whether in clinical trials or otherwise, cannot at this point in their medical care use Signatera as a substitute. *See* Doc. 5 at 31 (asking for an injunction that allows patients currently using RaDaR to continue use); Doc. 139 at 19. The Court agrees that avoiding disruption to ongoing treatment, research, and clinical studies is proper, and the preliminary injunction will be crafted to protect those interests.

E. CONCLUSION

Natera has shown that it is likely to succeed on the merits, it is likely to suffer irreparable harm in the absence of preliminary relief, the balance of equities tips in its favor, and an injunction is in the public interest. A preliminary injunction is appropriate.

It is **ORDERED** that Natera's preliminary injunction motion, Doc. 5, is **GRANTED**. The preliminary injunction will issue separately.

This the 27th day of December, 2023.



UNITED STATES DISTRICT JUDGE

IN THE UNITED STATES DISTRICT COURT
FOR THE MIDDLE DISTRICT OF NORTH CAROLINA

NATERA, INC.,)
)
Plaintiff,)
)
v.) 1:23-CV-629
)
NEOGENOMICS LABORATORIES,)
INC.,)
)
Defendant.)

PRELIMINARY INJUNCTION

Plaintiff Natera, Inc. moves for a preliminary injunction based on alleged infringement of two of its patents by defendant NeoGenomics Laboratories Inc. On consideration of the entire record, and as set forth in more detail in an order entered concurrently, the Court finds and concludes that Natera has demonstrated that it is likely to succeed on the merits of its claim. It is likely (1) NeoGenomics is infringing U.S. Patent No. 11,519,035 by making and selling the RaDaR assay, and NeoGenomics has not presented a substantial question of the validity of the asserted claims of the '035 patent; (2) Natera is substantially likely to suffer irreparable harm from NeoGenomics' ongoing infringement of the '035 patent; and (3) the balance of equities and the public interest favor protecting Natera and granting a preliminary injunction.

IT IS HEREBY ORDERED:


1. Natera's Motion for a Preliminary Injunction, Doc. 5, is **GRANTED**.
2. NeoGenomics and its privies, subsidiaries, affiliates, officers, agents, servants, employees, attorneys, and those acting or attempting to act in concert or

participation with them, are **ENJOINED** from (1) making, using, selling, or offering for sale in the United States the (a) the accused RaDaR assay (“the Accused Assay”) or (b) any assay or product not more than colorably different from the Accused Assay whose manufacture, use, importation, offer for sale, or sale would infringe any asserted claim of U.S. Patent No. 11,519,035; and (2) promoting, advertising, marketing, servicing, distributing, or supplying the above Accused Assay so as to induce others’ infringement.

3. Notwithstanding the foregoing, NeoGenomics may continue to make, use, and sell the Accused Assay solely for continued use of the Accused Assay
 - a. for those patients already using it before the entry of this injunction,
 - b. in support of research and development with other persons or entities on projects or studies that began before the entry of this injunction, or
 - c. for use in or in support of clinical trials in process or already approved by an agency of the United States.
4. NeoGenomics **SHALL**, within 10 days from the date of issuance of this Preliminary Injunction, provide notice and a copy of this Preliminary Injunction to (1) each of its privies, subsidiaries, affiliates, officers, agents, servants, employees, and attorneys; and (2) any other person or entity acting or attempting to act in concert or participation with NeoGenomics with respect to any of the enjoined activities, such that above persons and entities are duly noticed and bound by this Order under Federal Rule of Civil Procedure 65(d)(2). NeoGenomics shall further provide proof of each such notice to this

Court by filing proof of service within 14 days from the date of issuance of this
Preliminary Injunction.

This the 27th day of December, 2023.

A handwritten signature in black ink, appearing to read "L. L. [unclear]", written over a horizontal line.

UNITED STATES DISTRICT JUDGE



US011519035B2

(12) **United States Patent**
Rabinowitz et al.

(10) **Patent No.:** **US 11,519,035 B2**
(45) **Date of Patent:** ***Dec. 6, 2022**

(54) **METHODS FOR SIMULTANEOUS
AMPLIFICATION OF TARGET LOCI**

(71) Applicant: **Natera, Inc.**, San Carlos, CA (US)

(72) Inventors: **Matthew Rabinowitz**, San Francisco, CA (US); **Matthew Micah Hill**, Belmont, CA (US); **Bernhard Zimmermann**, Manteca, CA (US); **Johan Baner**, San Francisco, CA (US); **George Gemelos**, Portland, OR (US); **Milena Banjevic**, Los Altos Hills, CA (US); **Allison Ryan**, Belmont, CA (US); **Styrmir Sigurjonsson**, San Jose, CA (US); **Zachary Demko**, San Francisco, CA (US)

(73) Assignee: **Natera, Inc.**, San Carlos, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **16/934,407**

(22) Filed: **Jul. 21, 2020**

(65) **Prior Publication Data**
US 2020/0347454 A1 Nov. 5, 2020

Related U.S. Application Data

(63) Continuation of application No. 16/743,724, filed on Jan. 15, 2020, now Pat. No. 10,731,220, which is a continuation of application No. 16/399,268, filed on Apr. 30, 2019, now Pat. No. 10,538,814, which is a continuation of application No. 16/140,298, filed on Sep. 24, 2018, which is a continuation of application No. 14/918,544, filed on Oct. 20, 2015, now Pat. No. 10,316,362, which is a continuation-in-part of application No. 14/877,925, filed on Oct. 7, 2015, now abandoned, and a continuation-in-part of application No. 14/692,703, filed on Apr. 21, 2015, now Pat. No. 10,179,937, and a continuation-in-part of application No. 14/538,982, filed on Nov. 24, 2014, now Pat. No. 9,677,118, said application No. 14/877,925 is a continuation-in-part of application No. 14/225,356, filed on Mar. 25, 2014, now abandoned, and a continuation-in-part of application No. 13/780,022, filed on Feb. 28, 2013, now abandoned, and a continuation of application No. 13/683,604, filed on Nov. 21, 2012, now abandoned, said application No. 14/225,356 is a continuation of application No. PCT/US2012/058578, filed on Oct. 3, 2012, said application No. 13/780,022 is a continuation-in-part of application No. 13/683,604, filed on Nov. 21, 2012, now abandoned, and a continuation-in-part of application No. PCT/US2012/058578, filed on Oct. 3, 2012, and a continuation-in-part of application No. 13/335,043, filed on Dec. 22, 2011, now Pat. No. 10,113,196, and

a continuation-in-part of application No. 13/300,235, filed on Nov. 18, 2011, now Pat. No. 10,017,812, and a continuation-in-part of application No. 13/110,685, filed on May 18, 2011, now Pat. No. 8,825,412, said
(Continued)

(51) **Int. Cl.**
C12Q 1/68 (2018.01)
C12Q 1/6883 (2018.01)
C12Q 1/6811 (2018.01)
C12Q 1/6848 (2018.01)
C12Q 1/6809 (2018.01)
C12Q 1/6851 (2018.01)
C12Q 1/6844 (2018.01)
C12Q 1/6869 (2018.01)
C12Q 1/6855 (2018.01)
C12Q 1/6874 (2018.01)

(52) **U.S. Cl.**
CPC *C12Q 1/6883* (2013.01); *C12Q 1/6809* (2013.01); *C12Q 1/6811* (2013.01); *C12Q 1/6844* (2013.01); *C12Q 1/6848* (2013.01); *C12Q 1/6851* (2013.01); *C12Q 1/6855* (2013.01); *C12Q 1/6869* (2013.01); *C12Q 1/6874* (2013.01); *C12Q 2600/156* (2013.01)

(58) **Field of Classification Search**
None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,040,785 A 8/1977 Kim et al.
4,683,195 A 7/1987 Mullis et al.
(Continued)

FOREIGN PATENT DOCUMENTS

CN 1650032 A 8/2005
CN 1674028 A 9/2005
(Continued)

OTHER PUBLICATIONS

US 8,501,409 B2, 08/2013, Simen et al. (withdrawn)
(Continued)

Primary Examiner — Stephanie K Mummert

(57) **ABSTRACT**

The invention provides methods for simultaneously amplifying multiple nucleic acid regions of interest in one reaction volume as well as methods for selecting a library of primers for use in such amplification methods. The invention also provides library of primers with desirable characteristics, such as minimal formation of amplified primer dimers or other non-target amplicons.

15 Claims, 58 Drawing Sheets

Specification includes a Sequence Listing.

Related U.S. Application Data

application No. 13/683,604 is a continuation-in-part of application No. 13/300,235, filed on Nov. 18, 2011, now Pat. No. 10,017,812, and a continuation-in-part of application No. 13/110,685, filed on May 18, 2011, now Pat. No. 8,825,412, said application No. PCT/US2012/058578 is a continuation-in-part of application No. 13/300,235, filed on Nov. 18, 2011, now Pat. No. 10,017,812, said application No. 13/335,043 is a continuation-in-part of application No. 13/300,235, filed on Nov. 18, 2011, now Pat. No. 8,825,412, said application No. 13/110,685, filed on May 18, 2011, now Pat. No. 10,017,812, and a continuation-in-part of application No. 13/110,685, filed on May 18, 2011, now Pat. No. 8,825,412, said application No. 13/300,235 is a continuation-in-part of application No. 13/110,685, filed on May 18, 2011, now Pat. No. 8,825,412.

- (60) Provisional application No. 62/148,173, filed on Apr. 14, 2015, provisional application No. 62/146,188, filed on Apr. 10, 2015, provisional application No. 62/147,377, filed on Apr. 14, 2015, provisional application No. 62/066,514, filed on Oct. 21, 2014, provisional application No. 61/994,791, filed on May 16, 2014, provisional application No. 61/987,407, filed on May 1, 2014, provisional application No. 61/982,245, filed on Apr. 21, 2014, provisional application No. 61/634,431, filed on Feb. 29, 2012, provisional application No. 61/675,020, filed on Jul. 24, 2012, provisional application No. 61/683,331, filed on Aug. 15, 2012, provisional application No. 61/542,508, filed on Oct. 3, 2011, provisional application No. 61/426,208, filed on Dec. 22, 2010, provisional application No. 61/571,248, filed on Jun. 23, 2011, provisional application No. 61/516,996, filed on Apr. 12, 2011, provisional application No. 61/448,547, filed on Mar. 2, 2011, provisional application No. 61/462,972, filed on Feb. 9, 2011, provisional application No. 61/398,159, filed on Jun. 21, 2010, provisional application No. 61/395,850, filed on May 18, 2010.

6,214,558	B1	4/2001	Shuber et al.
6,221,603	B1	4/2001	Mahtani
6,258,540	B1	7/2001	Lo et al.
6,300,077	B1	10/2001	Shuber et al.
6,329,179	B1	12/2001	Kopreski
6,335,167	B1	1/2002	Pinkel et al.
6,440,706	B1	8/2002	Vogelstein et al.
6,479,235	B1	11/2002	Schumm et al.
6,489,135	B1	12/2002	Parrott et al.
6,605,451	B1	8/2003	Marmaro et al.
6,617,137	B2	9/2003	Dean et al.
6,720,140	B1	4/2004	Hartley et al.
6,858,412	B2	5/2004	Willis et al.
6,794,140	B1	9/2004	Goldsborough
6,807,491	B2	10/2004	Pavlovic et al.
6,927,028	B2	8/2005	Lo et al.
6,852,487	B1	10/2005	Barany et al.
6,958,211	B2	10/2005	Vingerhoets et al.
6,964,847	B1	11/2005	Englert
7,035,739	B2	4/2006	Schadt et al.
7,058,517	B1	6/2006	Denton et al.
7,058,616	B1	6/2006	Larder et al.
7,101,663	B2	9/2006	Godfrey et al.
7,153,656	B2	12/2006	Nolan et al.
7,218,764	B2	5/2007	Vaisberg et al.
7,297,485	B2	11/2007	Bornarth et al.
7,332,277	B2	2/2008	Dhallan
7,410,764	B2	8/2008	Gocke et al.
7,414,118	B1	8/2008	Mullah et al.
7,442,506	B2	12/2008	Dhallan
7,459,273	B2	12/2008	Jones et al.
7,645,576	B2	1/2010	Lo et al.
7,655,399	B2	2/2010	Cantor et al.
7,700,325	B2	4/2010	Cantor et al.
7,718,367	B2	5/2010	Lo et al.
7,718,370	B2	6/2010	Dhallan
7,727,720	B2	6/2010	Dhallan
7,741,463	B2	6/2010	Gormley et al.
7,790,418	B2	9/2010	Mayer
7,805,282	B2	9/2010	Casey et al.
7,838,647	B2	11/2010	Hahn et al.
7,981,609	B2	7/2011	Rubin et al.
7,888,017	B2	8/2011	Quake
8,008,018	B2	9/2011	Quake et al.
8,024,128	B2	9/2011	Rabinowitz
8,133,719	B2	3/2012	Drmanac et al.
8,137,912	B2	3/2012	Kapur et al.
8,173,370	B2	5/2012	Oeth et al.
8,168,389	B2	6/2012	Shoemaker et al.
8,236,503	B2	8/2012	Faham et al.
8,195,415	B2	10/2012	Fan et al.
8,296,076	B2	11/2012	Fan et al.
8,304,187	B2	11/2012	Fernando
8,318,430	B2*	11/2012	Chuu C12Q 1/6883 435/6.1

References Cited

U.S. PATENT DOCUMENTS

- 4,942,124 A 7/1990 Church et al.
- 5,486,477 A 1/1996 Carver
- 5,635,366 A 6/1997 Cooke et al.
- 5,648,220 A 7/1997 Bianchi et al.
- 5,716,776 A 2/1998 Bogart
- 5,753,467 A 5/1998 Jensen et al.
- 5,824,467 A 10/1998 Mascarenhas
- 5,854,033 A 12/1998 Lizardi
- 5,860,917 A 1/1999 Comanor et al.
- 5,891,734 A 4/1999 Gill et al.
- 5,952,170 A 9/1999 Stroun et al.
- 5,962,223 A 10/1999 Whiteley et al.
- 5,972,602 A 11/1999 Hyland et al.
- 5,976,790 A 11/1999 Pinkel et al.
- 5,994,148 A 11/1999 Stewart et al.
- 6,001,611 A 12/1999 Will
- 6,025,128 A 2/2000 Veltri et al.
- 6,066,454 A 5/2000 Lipshutz et al.
- 6,100,029 A 8/2000 Lapidus et al.
- 6,108,635 A 8/2000 Herren et al.
- 6,124,120 A 9/2000 Lizardi
- 6,143,496 A 11/2000 Brown et al.
- 6,156,504 A 12/2000 Gocke et al.
- 6,180,349 B1 1/2001 Ginzinger
- 6,235,472 B1 2/2001 Landegren et al.

8,318,434	B2	11/2012	Cuppens et al.
8,323,897	B2	12/2012	Andersen et al.
8,372,584	B2	2/2013	Shoemaker et al.
8,389,557	B2	3/2013	Singh et al.
8,389,578	B2	3/2013	Went et al.
8,450,063	B2	5/2013	Dube et al.
8,467,976	B2	8/2013	Lo et al.
8,515,679	B2	8/2013	Rabinowitz et al.
8,532,930	B2	9/2013	Rabinowitz et al.
8,679,741	B2	3/2014	Hoyal-Wrightson et al.
8,682,592	B2	3/2014	Rabinowitz et al.
8,703,652	B2	4/2014	Quake et al.
8,706,422	B2	4/2014	Lo et al.
8,748,103	B2	6/2014	Faham et al.
8,822,153	B2	9/2014	Hayes et al.
8,825,412	B2	9/2014	Rabinowitz et al.
9,005,894	B2	4/2015	Ladner et al.
9,051,602	B2	6/2015	Oliphant et al.
9,085,798	B2	7/2015	Chee
9,206,475	B2	12/2015	Gerdes et al.
9,228,234	B2	1/2016	Rabinowitz et al.
9,323,888	B2	4/2016	Rava et al.
9,404,150	B2	8/2016	Lee et al.
9,424,392	B2	8/2016	Rabinowitz et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

9,453,257 B2	9/2016	Hoyal-Wrightson et al.	2005/0009069 A1	1/2005	Liu et al.
9,476,095 B2	10/2016	Vogelstein et al.	2005/0043894 A1	2/2005	Fernandez
9,487,829 B2	11/2016	Vogelstein et al.	2005/0049793 A1	3/2005	Paterlini-brechot
9,493,828 B2	11/2016	Rava et al.	2005/0053950 A1	3/2005	Ubani et al.
9,506,119 B2	11/2016	Faham et al.	2005/0064476 A1	3/2005	Huang et al.
9,598,731 B2	3/2017	Talasaz	2005/0079521 A1	4/2005	Beaulieu et al.
9,677,118 B2	6/2017	Zimmermann et al.	2005/0079535 A1	4/2005	Kirchgesser et al.
10,017,810 B2	7/2018	Iafrate et al.	2005/0123914 A1	6/2005	Katz et al.
10,041,127 B2	8/2018	Talasaz	2005/0130173 A1	6/2005	Leamon et al.
10,061,890 B2	8/2018	Rabinowitz et al.	2005/0142577 A1	6/2005	Jones et al.
10,081,839 B2	9/2018	Rabinowitz et al.	2005/0144664 A1	6/2005	Smith et al.
10,083,273 B2	9/2018	Rabinowitz et al.	2005/0164241 A1	7/2005	Hahn et al.
10,174,369 B2	1/2019	Rabinowitz et al.	2005/0164252 A1	7/2005	Yeung
10,179,937 B2	1/2019	Babiarz et al.	2005/0216207 A1	9/2005	Kermani
10,227,652 B2	3/2019	Rabinowitz et al.	2005/0221341 A1	10/2005	Shimkets et al.
10,240,202 B2	3/2019	Rabinowitz et al.	2005/0227263 A1	10/2005	Green et al.
10,260,096 B2	4/2019	Rabinowitz et al.	2005/0250111 A1	11/2005	Xie et al.
10,266,893 B2	4/2019	Rabinowitz et al.	2005/0255508 A1	11/2005	Casey et al.
10,308,981 B2	6/2019	Sparks et al.	2005/0272073 A1	12/2005	Vaisberg et al.
10,316,362 B2	6/2019	Babiarz et al.	2005/0282185 A1	12/2005	Lo et al.
10,351,906 B2	7/2019	Zimmermann et al.	2006/0019278 A1	1/2006	Lo et al.
10,392,664 B2	8/2019	Rabinowitz et al.	2006/0040300 A1	2/2006	Dapprich et al.
10,450,597 B2	10/2019	Iafrate et al.	2006/0046258 A1	3/2006	Lapidus et al.
10,522,242 B2	12/2019	Rabinowitz et al.	2006/0051799 A1	3/2006	Iwaki et al.
10,526,658 B2	1/2020	Babiarz et al.	2006/0052945 A1	3/2006	Rabinowitz et al.
10,538,814 B2	1/2020	Babiarz et al.	2006/0057618 A1	3/2006	Piper et al.
10,557,172 B2	2/2020	Babiarz et al.	2006/0068394 A1	3/2006	Langmore et al.
10,597,708 B2	3/2020	Zimmermann et al.	2006/0088574 A1	4/2006	Manning et al.
10,597,709 B2	3/2020	Zimmermann et al.	2006/0094010 A1	5/2006	Giles et al.
10,597,723 B2	3/2020	Babiarz et al.	2006/0099614 A1	5/2006	Gill et al.
10,655,180 B2	5/2020	Babiarz et al.	2006/0121452 A1	6/2006	Dhallan
10,711,309 B2	7/2020	Rabinowitz et al.	2006/0134662 A1	6/2006	Pratt et al.
10,731,220 B2	8/2020	Babiarz et al.	2006/0141499 A1	6/2006	Sher et al.
10,774,380 B2	9/2020	Ryan et al.	2006/0141499 A1	6/2006	Sher et al.
10,793,912 B2	10/2020	Babiarz et al.	2006/0229823 A1	8/2006	Liu
10,894,976 B2	1/2021	Stray et al.	2006/0210997 A1	9/2006	Myerson et al.
11,111,543 B2	9/2021	Rabinowitz et al.	2006/0216153 A1	9/2006	Wobben et al.
11,111,544 B2	9/2021	Rabinowitz et al.	2006/0216738 A1	9/2006	Wada et al.
11,111,545 B2	9/2021	Babiarz et al.	2006/0228721 A1	10/2006	Leamon et al.
11,130,995 B2	9/2021	Quake et al.	2006/0248031 A1	11/2006	Kates et al.
2001/0051341 A1	12/2001	Lo et al.	2006/0281105 A1	12/2006	Li et al.
2001/0053519 A1	12/2001	Fodor et al.	2006/0292599 A1	12/2006	Ritz et al.
2002/0006622 A1	1/2002	Bradley et al.	2007/0020640 A1	1/2007	McCloskey et al.
2002/0107640 A1	8/2002	Ideker et al.	2007/0027636 A1	2/2007	Rabinowitz
2002/0119478 A1	8/2002	Umansky et al.	2007/0031857 A1	2/2007	Makarov et al.
2002/0182622 A1	12/2002	Nakamura et al.	2007/0037166 A1	2/2007	Wohlgemuth et al.
2003/0009295 A1	1/2003	Markowitz et al.	2007/0042384 A1	2/2007	Li et al.
2003/0040620 A1	2/2003	Langmore et al.	2007/0059700 A1	3/2007	Tao et al.
2003/0044388 A1	3/2003	Lo et al.	2007/0059707 A1	3/2007	Cantor et al.
2003/0065535 A1	4/2003	Karlov et al.	2007/0122805 A1	5/2007	Cantor et al.
2003/0077586 A1	4/2003	Pavlovic et al.	2007/0128624 A1	6/2007	Gormley et al.
2003/0087276 A1	5/2003	Kopreski	2007/0134658 A1	6/2007	Bohmer et al.
2003/0101000 A1	5/2003	Bader et al.	2007/0178478 A1	8/2007	Dhallan
2003/0119004 A1	6/2003	Wenz et al.	2007/0178501 A1	8/2007	Rabinowitz et al.
2003/0138780 A1	7/2003	Gill et al.	2007/0184467 A1	8/2007	Rabinowitz et al.
2003/0211489 A1	11/2003	Shen et al.	2007/0202525 A1	8/2007	Quake et al.
2003/0228613 A1	12/2003	Bornarth et al.	2007/0202536 A1	8/2007	Yamanishi et al.
2003/0232348 A1	12/2003	Jones et al.	2007/0207466 A1	9/2007	Cantor et al.
2003/0232353 A1	12/2003	Kennedy et al.	2007/0212689 A1	9/2007	Bianchi et al.
2004/0009518 A1	1/2004	Lo et al.	2007/0243549 A1	10/2007	Bischoff
2004/0033596 A1	2/2004	Threadgill et al.	2007/0259351 A1	11/2007	Chinitz
2004/0067493 A1	4/2004	Matsuzaki et al.	2008/0020390 A1	1/2008	Mitchell
2004/0096874 A1	5/2004	Neville et al.	2008/0026390 A1	1/2008	Stoughton et al.
2004/0115629 A1	6/2004	Panzer et al.	2008/0038733 A1	2/2008	Bischoff et al.
2004/0117346 A1	6/2004	Stoffel et al.	2008/0050739 A1	2/2008	Stoughton et al.
2004/0126760 A1	7/2004	Broude	2008/0070792 A1	3/2008	Stoughton
2004/0137470 A1	7/2004	Dhallan et al.	2008/0071076 A1	3/2008	Hahn et al.
2004/0146866 A1	7/2004	Fu	2008/0085836 A1	4/2008	Kearns et al.
2004/0157243 A1	8/2004	Huang et al.	2008/0090239 A1	4/2008	Shoemaker et al.
2004/0185495 A1	9/2004	Schueler et al.	2008/0096766 A1	4/2008	Lee
2004/0197797 A1	10/2004	Inoko et al.	2008/0102455 A1	5/2008	Poetter
2004/0209299 A1	10/2004	Pinter et al.	2008/0138809 A1	6/2008	Kapur et al.
2004/0229231 A1	11/2004	Frudakis et al.	2008/0182244 A1	7/2008	Tafas et al.
2004/0236518 A1	11/2004	Pavlovic et al.	2008/0193927 A1	8/2008	Mann et al.
2004/0259100 A1	12/2004	Gunderson et al.	2008/0220422 A1	9/2008	Shoemaker et al.
			2008/0234142 A1	9/2008	Lietz
			2008/0243398 A1	10/2008	Rabinowitz et al.
			2008/0280292 A1	11/2008	Wangh et al.
			2008/0286783 A1	11/2008	Hosono et al.
			2008/0299562 A1	12/2008	Oeth et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

2008/0305473	A1	12/2008	Chowdary et al.	2012/0010085	A1	1/2012	Rava et al.
2009/0023190	A1	1/2009	Lao et al.	2012/0028814	A1	2/2012	Toloue et al.
2009/0029377	A1	1/2009	Lo et al.	2012/0034603	A1	2/2012	Oliphant et al.
2009/0053719	A1	2/2009	Lo et al.	2012/0034685	A1	2/2012	Sparks et al.
2009/0087847	A1	4/2009	Lo et al.	2012/0108460	A1	5/2012	Quake et al.
2009/0098534	A1	4/2009	Weier et al.	2012/0122701	A1	5/2012	Ryan et al.
2009/0099041	A1	4/2009	Church et al.	2012/0165203	A1	6/2012	Quake et al.
2009/0143570	A1	6/2009	Jiang et al.	2012/0185176	A1	7/2012	Rabinowitz et al.
2009/0176662	A1	7/2009	Rigatti et al.	2012/0190020	A1	7/2012	Oliphant et al.
2009/0221620	A1	9/2009	Luke et al.	2012/0190021	A1	7/2012	Oliphant et al.
2009/0228299	A1	9/2009	Kangarloo et al.	2012/0190557	A1	7/2012	Oliphant et al.
2009/0263800	A1	10/2009	Wohlgemuth et al.	2012/0191358	A1	7/2012	Oliphant et al.
2009/0280479	A1	11/2009	Hoon et al.	2012/0196754	A1	8/2012	Quake et al.
2009/0317817	A1	12/2009	Oeth et al.	2012/0208706	A1	8/2012	Downing et al.
2010/0035232	A1	2/2010	Ecker et al.	2012/0214678	A1	8/2012	Rava et al.
2010/0041048	A1	2/2010	Diehl et al.	2012/0264121	A1	10/2012	Rava et al.
2010/0086914	A1	4/2010	Bentley et al.	2012/0264618	A1	10/2012	Nygren
2010/0105049	A1	4/2010	Ehrlich et al.	2012/0270212	A1	10/2012	Rabinowitz et al.
2010/0112575	A1*	5/2010	Fan C12Q 1/6883 435/6.11	2012/0270739	A1	10/2012	Rava et al.
2010/0112586	A1	5/2010	Stoughton et al.	2012/0295810	A1	11/2012	Quake et al.
2010/0112590	A1	5/2010	Lo et al.	2012/0295819	A1	11/2012	Leamon et al.
2010/0120038	A1	5/2010	Mir et al.	2013/0017549	A1	1/2013	Hong
2010/0124751	A1	5/2010	Quake et al.	2013/0022973	A1	1/2013	Hansen et al.
2010/0129792	A1	5/2010	Makrigiorgos	2013/0024127	A1	1/2013	Stuelpnagel
2010/0129874	A1	5/2010	Mitra et al.	2013/0034546	A1	2/2013	Rava et al.
2010/0138165	A1	6/2010	Fan et al.	2013/0040375	A1	2/2013	Sparks et al.
2010/0171954	A1	7/2010	Quake et al.	2013/0060483	A1	3/2013	Struble et al.
2010/0173394	A1	7/2010	Colston et al.	2013/0069869	A1	3/2013	Akao et al.
2010/0184043	A1	7/2010	Mitchell et al.	2013/0085681	A1	4/2013	Deciu et al.
2010/0184069	A1	7/2010	Fernando et al.	2013/0090250	A1	4/2013	Sparks et al.
2010/0184152	A1	7/2010	Sandler	2013/0116130	A1	5/2013	Fu et al.
2010/0196892	A1	8/2010	Quake et al.	2013/0123120	A1	5/2013	Zimmermann et al.
2010/0203538	A1	8/2010	Dube et al.	2013/0130923	A1	5/2013	Ehrlich et al.
2010/0216151	A1	8/2010	Lapdus et al.	2013/0157870	A1	6/2013	Pushkarev et al.
2010/0216153	A1	8/2010	Lapidus et al.	2013/0172211	A1	7/2013	Oliphant et al.
2010/0248231	A1	9/2010	Wei et al.	2013/0178373	A1	7/2013	Rabinowitz et al.
2010/0255492	A1	10/2010	Quake et al.	2013/0190653	A1	7/2013	Alvarez Ramos
2010/0256013	A1	10/2010	Quake et al.	2013/0196862	A1	8/2013	Rabinowitz et al.
2010/0273159	A1	10/2010	Melo	2013/0210644	A1	8/2013	Stoughton et al.
2010/0273219	A1	10/2010	May et al.	2013/0225422	A1	8/2013	Rabinowitz et al.
2010/0273678	A1	10/2010	Alexandre et al.	2013/0237431	A1	9/2013	Lo et al.
2010/0285478	A1	11/2010	Chen et al.	2013/0252824	A1	9/2013	Rabinowitz et al.
2010/0285537	A1	11/2010	Zimmermann	2013/0253369	A1	9/2013	Rabinowitz et al.
2010/0291572	A1	11/2010	Stoughton et al.	2013/0261004	A1	10/2013	Ryan et al.
2010/0291635	A1	11/2010	Peleg	2013/0274116	A1	10/2013	Rabinowitz et al.
2010/0323352	A1	12/2010	Lo et al.	2013/0288252	A1	10/2013	Sparks et al.
2011/0015096	A1	1/2011	Chiu	2013/0303461	A1	11/2013	Iafrate et al.
2011/0033862	A1	2/2011	Rabinowitz et al.	2013/0310260	A1	11/2013	Kim et al.
2011/0039724	A1	2/2011	Lo et al.	2013/0323731	A1	12/2013	Lo et al.
2011/0045462	A1	2/2011	Fu et al.	2013/0325360	A1	12/2013	Deciu et al.
2011/0064824	A1	3/2011	Lascoste et al.	2014/0032128	A1	1/2014	Rabinowitz et al.
2011/0071031	A1	3/2011	Khripin et al.	2014/0038830	A1	2/2014	Srinivasan et al.
2011/0086769	A1	4/2011	Oliphant et al.	2014/0051585	A1	2/2014	Prosen et al.
2011/0092763	A1	4/2011	Rabinowitz et al.	2014/0065621	A1	3/2014	Mhatre et al.
2011/0105353	A1	5/2011	Lo et al.	2014/0066317	A1	3/2014	Talasaz
2011/0130558	A1	6/2011	Ritt et al.	2014/0087385	A1	3/2014	Rabinowitz et al.
2011/0151442	A1	6/2011	Fan et al.	2014/0094373	A1	4/2014	Zimmermann et al.
2011/0159499	A1	6/2011	Hindson et al.	2014/0100126	A1	4/2014	Rabinowitz
2011/0160078	A1	6/2011	Fodor et al.	2014/0100134	A1	4/2014	Rabinowitz et al.
2011/0178719	A1	7/2011	Rabinowitz et al.	2014/0106975	A1	4/2014	Stoughton et al.
2011/0201507	A1	8/2011	Rava et al.	2014/0141981	A1	5/2014	Zimmermann et al.
2011/0212446	A1	9/2011	Wang et al.	2014/0154682	A1	6/2014	Rabinowitz et al.
2011/0212846	A1	9/2011	Spier	2014/0155274	A1	6/2014	Xie et al.
2011/0224087	A1	9/2011	Quake et al.	2014/0162269	A1	6/2014	Rabinowitz
2011/0246083	A1	10/2011	Fan et al.	2014/0186827	A1	7/2014	Pieprzyk et al.
2011/0251149	A1	10/2011	Perrine et al.	2014/0193816	A1	7/2014	Rabinowitz et al.
2011/0288780	A1	11/2011	Rabinowitz et al.	2014/0206552	A1	7/2014	Rabinowitz et al.
2011/0294699	A1	12/2011	Lee et al.	2014/0227691	A1	8/2014	May et al.
2011/0300608	A1	12/2011	Ryan et al.	2014/0227705	A1	8/2014	Vogelstein et al.
2011/0301854	A1	12/2011	Curry et al.	2014/0242588	A1	8/2014	Van Den Boom et al.
2011/0312503	A1	12/2011	Chuu et al.	2014/0256558	A1	9/2014	Varley et al.
2011/0318734	A1	12/2011	Lo et al.	2014/0256569	A1	9/2014	Rabinowitz et al.
2012/0003635	A1	1/2012	Lo et al.	2014/0272956	A1	9/2014	Huang et al.
2012/0003637	A1	1/2012	Lo et al.	2014/0274740	A1	9/2014	Srinivasan et al.
				2014/0287934	A1	9/2014	Szelinger et al.
				2014/0296081	A1	10/2014	Diehn et al.
				2014/0329245	A1	11/2014	Spier et al.
				2014/0336060	A1	11/2014	Rabinowitz
				2015/0051087	A1	2/2015	Rabinowitz et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

2015/0064695	A1	3/2015	Katz et al.	2019/0211393	A1	7/2019	Rabinowitz et al.
2015/0086477	A1	3/2015	Mitchell et al.	2019/0211399	A1	7/2019	Rabinowitz et al.
2015/0087535	A1	3/2015	Patel	2019/0211402	A1	7/2019	Babiarz et al.
2015/0147815	A1	5/2015	Babiarz et al.	2019/0211406	A1	7/2019	Babiarz et al.
2015/0167069	A1	6/2015	Schutz et al.	2019/0249241	A1	8/2019	Rabinowitz et al.
2015/0197786	A1	7/2015	Osborne et al.	2019/0256894	A1	8/2019	Zimmermann et al.
2015/0211050	A1	7/2015	Iafrate et al.	2019/0256906	A1	8/2019	Rabinowitz et al.
2015/0218631	A1	8/2015	Chuu et al.	2019/0256907	A1	8/2019	Ryan et al.
2015/0232938	A1	8/2015	Mhatre	2019/0256908	A1	8/2019	Rabinowitz et al.
2015/0265995	A1	9/2015	Head et al.	2019/0256909	A1	8/2019	Rabinowitz et al.
2015/0299812	A1	10/2015	Talasz	2019/0256912	A1	8/2019	Rabinowitz et al.
2015/0315657	A1	11/2015	Rhodes et al.	2019/0256916	A1	8/2019	Babiarz et al.
2015/0322507	A1	11/2015	Zimmermann et al.	2019/0256917	A1	8/2019	Babiarz et al.
2015/0329891	A1	11/2015	Tan et al.	2019/0256919	A1	8/2019	Babiarz et al.
2016/0032396	A1	2/2016	Diehn et al.	2019/0256924	A1	8/2019	Vogelstein et al.
2016/0046986	A1	2/2016	Eltoukhy et al.	2019/0256931	A1	8/2019	Babiarz et al.
2016/0115541	A1	4/2016	Schutz et al.	2019/0264277	A1	8/2019	Rabinowitz et al.
2016/0145682	A1	5/2016	Woodward et al.	2019/0264280	A1	8/2019	Rabinowitz et al.
2016/0186239	A1	6/2016	Sinha	2019/0264288	A1	8/2019	Rabinowitz et al.
2016/0186253	A1	6/2016	Talasz et al.	2019/0271043	A1	9/2019	Babiarz et al.
2016/0201124	A1	7/2016	Donahue et al.	2019/0276888	A1	9/2019	Rabinowitz et al.
2016/0239602	A1	8/2016	Shendure et al.	2019/0284623	A1	9/2019	Rabinowitz et al.
2016/0244838	A1	8/2016	Babiarz et al.	2019/0300950	A1	10/2019	Rabinowitz et al.
2016/0257993	A1	9/2016	Fu et al.	2019/0309358	A1	10/2019	Rabinowitz et al.
2016/0289740	A1	10/2016	Fu et al.	2019/0309359	A1	10/2019	Zimmermann et al.
2016/0289753	A1	10/2016	Osborne et al.	2019/0309365	A1	10/2019	Babiarz et al.
2016/0312276	A1	10/2016	Fu et al.	2019/0316177	A1	10/2019	Zimmermann et al.
2016/0319345	A1	11/2016	Gnerre et al.	2019/0316184	A1	10/2019	Zimmermann et al.
2016/0369333	A1	12/2016	Babiarz et al.	2019/0316200	A1	10/2019	Rabinowitz et al.
2017/0011166	A1	1/2017	Rabinowitz et al.	2019/0323076	A1	10/2019	Rabinowitz et al.
2017/0107576	A1	4/2017	Babiarz et al.	2019/0360036	A1	11/2019	Rabinowitz et al.
2017/0114411	A1	4/2017	Mitchell et al.	2020/0024653	A1	1/2020	Bethke
2017/0121716	A1	5/2017	Rodi et al.	2020/0032323	A1	1/2020	Talasz et al.
2017/0152561	A1	6/2017	Hamamah et al.	2020/0109449	A1	4/2020	Stamm et al.
2017/0218458	A1	8/2017	Fan et al.	2020/0123612	A1	4/2020	Babiarz et al.
2017/0275689	A1	9/2017	Maguire et al.	2020/0126634	A1	4/2020	Sigurjonsson et al.
2017/0283788	A1	10/2017	Khoja et al.	2020/0140950	A1	5/2020	Babiarz et al.
2017/0314014	A1	11/2017	Green et al.	2020/0149111	A1	5/2020	Babiarz et al.
2017/0342477	A1	11/2017	Jensen et al.	2020/0157629	A1	5/2020	Babiarz et al.
2017/0362649	A1	12/2017	Lieberman-Aiden et al.	2020/0172977	A1	6/2020	Rabinowitz et al.
2018/0023128	A1	1/2018	Yanai et al.	2020/0181697	A1	6/2020	Rabinowitz et al.
2018/0025109	A1	2/2018	Rabinowitz et al.	2020/0190570	A1	6/2020	Ryan et al.
2018/0127744	A1	5/2018	Hu et al.	2020/0190573	A1	6/2020	Rabinowitz et al.
2018/0148777	A1	5/2018	Kirkizlar et al.	2020/0190591	A1	6/2020	Rabinowitz et al.
2018/0155775	A1	6/2018	Zimmermann et al.	2020/0208196	A1	7/2020	Zimmermann et al.
2018/0155776	A1	6/2018	Zimmermann et al.	2020/0208221	A1	7/2020	Babiarz et al.
2018/0155779	A1	6/2018	Zimmermann et al.	2020/0224273	A1	7/2020	Rabinowitz et al.
2018/0155785	A1	6/2018	Rabinowitz et al.	2020/0232036	A1	7/2020	Rabinowitz et al.
2018/0155786	A1	6/2018	Rabinowitz et al.	2020/0232037	A1	7/2020	Babiarz et al.
2018/0155792	A1	6/2018	Rabinowitz et al.	2020/0248264	A1	8/2020	Rabinowitz et al.
2018/0171409	A1	6/2018	Rabinowitz et al.	2020/0248266	A1	8/2020	Swanton et al.
2018/0171420	A1	6/2018	Babiarz et al.	2020/0316498	A1	10/2020	Mitchell
2018/0173845	A1	6/2018	Sigurjonsson et al.	2020/0318191	A1	10/2020	Babiarz et al.
2018/0173846	A1	6/2018	Sigurjonsson et al.	2020/0350034	A1	11/2020	Rabinowitz et al.
2018/0187241	A1	7/2018	Selvaraj et al.	2020/0362415	A1	11/2020	Rabinowitz et al.
2018/0201995	A1	7/2018	Rabinowitz et al.	2020/0407788	A1	12/2020	Ryan et al.
2018/0237841	A1	8/2018	Stray et al.	2020/0407798	A1	12/2020	Babiarz et al.
2018/0251553	A1	9/2018	McGranahan et al.	2021/0009990	A1	1/2021	Stray et al.
2018/0265917	A1	9/2018	Barany et al.	2021/0025005	A1	1/2021	Babiarz et al.
2018/0288982	A1	10/2018	Sinha	2021/0054459	A1	2/2021	Rabinowitz et al.
2018/0298439	A1	10/2018	Ryan et al.	2021/0071246	A1	3/2021	Zimmermann et al.
2018/0300448	A1	10/2018	Rabinowitz et al.	2021/0139969	A1	5/2021	Mitchell et al.
2018/0320171	A1	11/2018	Withey	2021/0139983	A1	5/2021	Mitchell et al.
2019/0010543	A1	1/2019	Babiarz et al.	2021/0139988	A1	5/2021	Mitchell et al.
2019/0106737	A1	4/2019	Underhill	2021/0155988	A1	5/2021	Rabinowitz et al.
2019/0106751	A1	4/2019	Zimmermann et al.	2021/0189498	A1	6/2021	Babiarz et al.
2019/0185913	A1	6/2019	Zimmermann et al.	2021/0198733	A1	7/2021	Moshkevich et al.
2019/0185936	A1	6/2019	Babiarz et al.	2021/0198742	A1	7/2021	Rabinowitz et al.
2019/0194743	A1	6/2019	Ryan et al.	2021/0198743	A1	7/2021	Rabinowitz et al.
2019/0194758	A1	6/2019	Babiarz et al.	2021/0222230	A1	7/2021	Zimmermann et al.
2019/0194759	A1	6/2019	Babiarz et al.	2021/0222240	A1	7/2021	Moshkevich et al.
2019/0203290	A1	7/2019	Rabinowitz et al.	2021/0257048	A1	8/2021	Zimmermann B et al.
2019/0203294	A1	7/2019	Babiarz et al.	2021/0269879	A1	9/2021	Mitchell et al.
2019/0211391	A1	7/2019	Rabinowitz et al.	2021/0324463	A1	10/2021	Rabinowitz et al.
2019/0211392	A1	7/2019	Rabinowitz et al.	2021/0327538	A1	10/2021	Egilsson et al.
				2021/0327542	A1	10/2021	Ryan et al.
				2021/0355536	A1	11/2021	Rabinowitz et al.
				2022/0025455	A1	1/2022	Zimmermann et al.
				2022/0025456	A1	1/2022	Rabinowitz et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

2022/0033908 A1 2/2022 Rabinowitz et al.
 2022/0033909 A1 2/2022 Babiarz et al.
 2022/0042103 A1 2/2022 Rabinowitz et al.
 2022/0056509 A1 2/2022 Zimmermann
 2022/0056534 A1 2/2022 Rivers
 2022/0009866 A1 3/2022 Rabinowitz et al.
 2022/0073978 A1 3/2022 Rabinowitz et al.
 2022/0073979 A1 3/2022 Rabinowitz et al.

FOREIGN PATENT DOCUMENTS

CN 101675169 A 3/2010
 CN 104736722 A 6/2015
 CN 105229175 A 1/2016
 EP 0270017 A2 6/1988
 EP 1325963 A1 7/2003
 EP 1524321 A1 4/2005
 EP 1325963 B1 9/2006
 EP 1524321 B1 7/2009
 EP 2163622 A1 3/2010
 EP 2128169 A1 12/2010
 EP 2902500 A1 8/2015
 EP 3026124 A1 6/2016
 EP 3285193 A1 2/2018
 EP 2877594 B1 12/2019
 EP 3187597 B1 6/2020
 EP 3134541 B1 8/2020
 EP 3760730 A1 1/2021
 EP 3760731 A1 1/2021
 EP 3760732 A1 1/2021
 EP 3824470 5/2021
 EP 3443119 B1 2/2022
 GB 2488358 8/2012
 JP 2965699 8/1999
 JP 2002-530121 A 9/2002
 JP 2002/300894 A 10/2002
 JP 2003/521252 A 7/2003
 JP 2004502466 A 1/2004
 JP 2004533243 A 11/2004
 JP 2005514956 A 5/2005
 JP 2005160470 A 6/2005
 JP 2006-254912 A 9/2006
 JP 2008-263974 A 11/2008
 JP 2008/271980 A 11/2008
 JP 2010-509922 A 4/2010
 JP 2011/508662 A 3/2011
 JP 2011/516069 A 5/2011
 JP 2015-535681 12/2015
 RU 2290078 C1 12/2006
 WO 95/01796 1/1995
 WO 98/39474 9/1998
 WO 98/44151 10/1998
 WO 00/18957 4/2000
 WO 01/34844 A1 5/2001
 WO 01/57269 A2 8/2001
 WO 179851 A1 10/2001
 WO 200190419 A2 11/2001
 WO 2002004672 A2 1/2002
 WO 02/44411 A1 6/2002
 WO 2002055985 A2 7/2002
 WO 02/070751 A1 9/2002
 WO 2002076377 10/2002
 WO 02/090505 A2 11/2002
 WO 03/000919 A2 1/2003
 WO 03/018757 A3 3/2003
 WO 03/020974 A3 3/2003
 WO 2003031646 A1 4/2003
 WO 3050532 A1 6/2003
 WO 2003062441 A1 7/2003
 WO 3102595 A1 12/2003
 WO 3106623 A2 12/2003
 WO 2004/051218 A2 6/2004
 WO 2004069849 A2 8/2004
 WO 2004070005 A2 8/2004
 WO 2004070007 A2 8/2004

WO 2004087863 A2 10/2004
 WO 2005003375 A2 1/2005
 WO 2005021793 A1 3/2005
 WO 2005023091 A2 3/2005
 WO 2005030999 A1 4/2005
 WO 2005035725 A2 4/2005
 WO 2005/039389 A3 5/2005
 WO 2005100401 A2 10/2005
 WO 2005123779 A2 12/2005
 WO 2007145612 A1 6/2006
 WO 2006110855 A2 10/2006
 WO 2006/128192 A2 11/2006
 WO 2007/011903 A3 1/2007
 WO 2007/052006 A1 5/2007
 WO 2007057647 A1 5/2007
 WO 2007062164 A3 5/2007
 WO 2007/073171 A2 6/2007
 WO 2007070280 A2 6/2007
 WO 2007070482 A2 6/2007
 WO 2007075836 A2 7/2007
 WO 2007/092473 A2 8/2007
 WO 2007086935 A2 8/2007
 WO 2007/117256 A1 10/2007
 WO 2007117039 A1 10/2007
 WO 2007132167 A2 11/2007
 WO 2007/147073 A2 12/2007
 WO 2007/147076 A2 12/2007
 WO 2007140417 A2 12/2007
 WO 2007147074 A2 12/2007
 WO 2007147079 A2 12/2007
 WO 2008024473 A2 2/2008
 WO 2008048931 A1 4/2008
 WO 2008/061213 A2 5/2008
 WO 2008051928 A2 5/2008
 WO 2008056937 A1 5/2008
 WO 2008059578 A1 5/2008
 WO 2008079374 A2 7/2008
 WO 2008081451 A2 7/2008
 WO 2008084405 A2 7/2008
 WO 2008115427 A2 9/2008
 WO 2008115497 A2 9/2008
 WO 2008118988 A1 10/2008
 WO 2008135837 A2 11/2008
 WO 2008157264 A2 12/2008
 WO 2009009769 A2 1/2009
 WO 2009013492 A1 1/2009
 WO 2009013496 A1 1/2009
 WO 2009019215 A1 2/2009
 WO 2009019455 A2 2/2009
 WO 2009/032779 A2 3/2009
 WO 2009/036525 A2 3/2009
 WO 2009030100 A1 3/2009
 WO 2009032781 A2 3/2009
 WO 2009033178 A1 3/2009
 WO 2009049889 A1 4/2009
 WO 2009017784 A2 5/2009
 WO 2009064897 A2 5/2009
 WO 2009091934 A1 7/2009
 WO 2009092035 A2 7/2009
 WO 2009/105531 A1 8/2009
 WO 2009099602 A1 8/2009
 WO 2009100029 A1 8/2009
 WO 2009105531 A1 8/2009
 WO 2009117122 A2 9/2009
 WO 2009120808 A2 10/2009
 WO 2009145828 A2 12/2009
 WO 2009146335 A1 12/2009
 WO 2010014920 A1 2/2010
 WO 2010017214 A1 2/2010
 WO 2010033578 A1 2/2010
 WO 2010/033639 A2 3/2010
 WO 2010/033652 A1 3/2010
 WO 2010042831 A2 4/2010
 WO 2010045617 A2 4/2010
 WO 2010075459 7/2010
 WO 2010/088288 A2 8/2010
 WO 2010115016 A2 10/2010
 WO 2010115154 A1 10/2010
 WO 2010118016 A2 10/2010

(56)

References Cited

FOREIGN PATENT DOCUMENTS

WO 2010/127186 A1 11/2010
 WO 2011/023078 A1 3/2011
 WO 2011/032078 A1 3/2011
 WO 2011/041485 A1 4/2011
 WO 2011/051283 A1 5/2011
 WO 2011/057061 A1 5/2011
 WO 2011/057094 A1 5/2011
 WO 2011/090556 A1 7/2011
 WO 2011/087760 A1 7/2011
 WO 2011/102998 A2 8/2011
 WO 2011/118603 A1 9/2011
 WO 2011/109440 A1 9/2011
 WO 2011/140433 A2 11/2011
 WO 2011/146632 A1 11/2011
 WO 2012/019200 A2 2/2012
 WO 2012/028746 A1 3/2012
 WO 2012/042374 A2 4/2012
 WO 2012/058488 A1 5/2012
 WO 2012/283250 A1 6/2012
 WO 2012/088456 A2 6/2012
 WO 2012/0071621 A1 6/2012
 WO 2012/108920 A1 8/2012
 WO 2012/142531 A2 10/2012
 WO 2007/149791 A2 12/2012
 WO 2013/030577 A1 3/2013
 WO 2013/045432 A1 4/2013
 WO 2013/049892 A1 4/2013
 WO 2013/052557 A2 4/2013
 WO 2013/078470 A2 5/2013
 WO 2013/086464 A1 6/2013
 WO 2013/123220 A1 8/2013
 WO 2013/138510 A1 9/2013
 WO 2013/138510 A9 9/2013
 WO 2013/0130848 A1 9/2013
 WO 2013/159035 A2 10/2013
 WO 2013/169339 A1 11/2013
 WO 2013/177220 A1 11/2013
 WO 2013/181651 A1 12/2013
 WO 2014/004726 A1 1/2014
 WO 2014/014497 A1 1/2014
 WO 2014/0018080 A1 1/2014
 WO 2014/035986 A1 3/2014
 WO 2014/122288 A1 8/2014
 WO 2014/145078 A1 9/2014
 WO 2014/145232 A2 9/2014
 WO 2014/149134 A2 9/2014
 WO 2014/150300 A2 9/2014
 WO 2014/151117 A1 9/2014
 WO 2014/194113 A2 12/2014
 WO 2015/134552 A1 3/2015
 WO 2015/048535 A1 4/2015
 WO 2015/100427 A1 7/2015
 WO 2015/148494 A1 10/2015
 WO 2015/164432 A1 10/2015
 WO 2016/009059 A1 1/2016
 WO 2016/009224 A1 1/2016
 WO 2016/063122 A1 4/2016
 WO 2016/065295 A1 4/2016
 WO 2016/077313 A1 5/2016
 WO 2016/123698 A1 8/2016
 WO 2016/138080 A1 9/2016
 WO 2016/176662 A1 11/2016
 WO 2016/183106 A1 11/2016
 WO 2016/193490 A1 12/2016
 WO 2017/058784 A1 4/2017
 WO 2017/181146 A1 10/2017
 WO 2017/181202 A2 10/2017
 WO 2017/190106 A1 11/2017
 WO 2017/205540 A1 11/2017
 WO 2018/009723 A1 1/2018
 WO 2018/083467 A1 5/2018
 WO 2018/085603 A1 5/2018
 WO 2018/106798 A1 6/2018
 WO 2018/136562 A2 7/2018
 WO 2018/156418 A1 8/2018

WO 2018/237081 A1 12/2018
 WO 2019/046817 A1 3/2019
 WO 2019/118926 A1 6/2019
 WO 2019/140298 A1 7/2019
 WO 2019/161244 A1 8/2019
 WO 2019/200228 A1 10/2019
 WO 2019/241349 A1 12/2019
 WO 2020/010255 A1 1/2020
 WO 2020/018522 A1 1/2020
 WO 2020/041449 A1 2/2020
 WO 2020/076957 A1 4/2020
 WO 2020/106987 A1 5/2020
 WO 2020/131699 A2 6/2020
 WO 2020/214547 A1 10/2020
 WO 2020/247263 A1 12/2020
 WO 2021/055968 A1 3/2021
 WO 2007/100911 A2 9/2021
 WO 2021/243045 A1 12/2021
 WO 2022/015676 A1 1/2022

OTHER PUBLICATIONS

Wright et al. (Hum Reprod Updt, 2009, 15(1):139-151) (Year: 2009).*

Cronn et al. (Nucleic Acids Research 2008, 36(19):e122) (Year: 2008).*

Su et al. (J of Molec Diagn, 2011, 13(1):74-84) (Year: 2011).*

Bashashati, A. et al., "Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling", Journal of Pathology, vol. 231, 2013, 21-34.

Binladen, J. et al., "The Use of Coded PCR Primers Enables High-Throughput Sequencing of Multiple Homolog Amplification Products by 454 Parallel Sequencing", PLOS One, Issue 2, Feb. 2007, 9 pages.

De Jong, M. M. et al., "Genes other than BRCA 1 and BRCA2 involved in breast cancer susceptibility", J. Med. Genet., vol. 39, 2009, 225-242.

Faham, M. et al., "Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia", Blood Journal, vol. 120, No. 26, Dec. 20, 2012, 5173-5180.

Gao, F. et al., "Characterizing Immunoglobulin Repertoire from Whole Blood by a Personal Genome Sequencer", PLOS One, vol. 8, No. 9, Sep. 13, 2013, 8 pgs.

Gnrirke, A. et al., "Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing", Nature Biotechnology, vol. 27, No. 2, Feb. 2009, 182-189.

Hodgkinson, C. L. et al., "Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer", Nature Medicine, vol. 20, No. 8, Aug. 2014, 897-905.

Hou, X. et al., "Analysis of the Repertoire Features of TCR Beta Chain CDR3 in Human by High-Throughput Sequencing", Cellular Physiology and Biochemistry, vol. 39, Jul. 21, 2019, 651-667.

Illumina, "MiSeq System Information Sheet", 2018, 3 pgs.

Keller, M. C. et al., "Non-Pathological Paternal Isodisomy of Chromosome 2 Detected From a Genome-Wide SNP Scan", American Journal of Medical Genetics, Part A, 2009, 1823-1826.

Kukita, Y. et al., "High-fidelity target sequencing of individual molecules identified using barcode sequences: de nova detection and absolute quantitation of mutations in plasma cell-free DNA from cancer patients", DNA Research, vol. 22, No. 4, Jun. 29, 2015, 269-277.

Scarpa, A. et al., "Molecular Typing of Lung Adenocarcinoma on Cytological Samples Using a Multigene Next Generation Sequencing Panel", PLOS One, vol. 8, No. 11, Nov. 13, 2013, 6 pgs.

Short, N. J. et al., "Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia", Blood Advances, vol. 4, No. 8, Apr. 23, 2020, 1670-1677.

Siebert, P. D. et al., "An improved PCR method for walking in uncloned genomic DNA", Nucleic Acids Research, vol. 23, No. 6, 1995, 1087-1088.

Tewhey, R. et al., "Microdroplet-based PCR enrichment for large-scale targeted sequencing", Nature Biotechnology, vol. 27, No. 11, Nov. 2009, 1025-1031.

(56)

References Cited

OTHER PUBLICATIONS

- Zhou, W. et al., "Counting alleles to predict recurrence of early-stage colorectal cancers", *The Lancet*, vol. 359, Jan. 19, 2002, 219-225.
- "European Application No. 014198110, European Search Report dated Apr. 28, 2015, 3 pages."
- "Finishing the Euchromatic Sequence of the Human Genome", *Nature* vol. 431,(Oct. 21, 2004),931-945.
- "FixedMedium, dictionary definition, Academic Press Dictionary of Science and Technology", Retrieved from the Internet: <URL:www.credoreference.com/entry/apdst/fixed_medium>, 1996, 1 pg.
- "GeneticsHome Reference", <http://ghr.nlm.nih.gov/handbook/genomicresearch/snp>, Feb. 28, 2014, 1-2.
- "Ion Ampli Seq Comprehensive Cancer Panel, product brochure, Life Technologies Corporation. Retrieved from the Internet", <URL:https://tools.lifetechnologies.com/content/sfs/brochures/ion_comp_cancerpanel_flyer.pdf>, 2012, 2 pgs.
- "Multiplexing with RainDrop Digital PCR", RainDance Technologies, Application Note, 2013, 1-2.
- "NucleicAcids, Linkers and Primers: Random Primers", New England Biolabs 1998/99Catalog, 1998, 121 and 284.
- "PRIMER3, information sheet, Sourceforge.net. [retrieved on Nov. 12, 2012]. Retrieved from the Internet: <URL: <http://primer3.sourceforge.net/>>, 2009, 1 pg.
- "Db SNP rs2056688 (http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2056688, downloaded May 4, 2015)", 3 pages.
- PRNewswire (Research Suggests Daily Consumption of Orange Juice Can Reduce Blood Pressure and May Provide Beneficial Effects to Blood Vessel Function: New Study Identified Health Benefits in Orange Juice, Dec. 8, 2010), 3 pages.
- What to Expect (Weird Harmony results, May 1, 2015), 7 pages.
- The Bump (Panorama Test, attached, Jul. 1, 2013), 8 pages.
- "Blast of AAAAAAAAAATTTAAAAAAAAATTT(<http://blast.ncbi.nlm.nih.gov/Blast.cgi>, downloaded May 4, 2015)", 9 pages.
- "Guideline related to genetic examination", Societies Related to Genetic Medicine, Japanese Society for Genetic Counseling, Japanese Society for Gene Diagnosis and Therapy, Japan Society of Obstetrics and Gynecology, 2003, 2-15.
- "How Many Carbs in a Potato?, [Online]", Retrieved from the Internet: <<http://www.newhealthguide.org/How-Many-Carbs-In-A-Potato.html>>, Nov. 1, 2014, 3 pages.
- "Random variable", In The Penguin Dictionary of Mathematics. Retrieved from http://www.credoreference.com/entry/penguinmath/random_variable, 2008, 1 page.
- Abbosh, C. et al., "Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution", *Nature*, vol. 545, May 25, 2017, 446-451.
- Abidi, S. et al., "Leveraging XML-based electronic medical records to extract experiential clinical knowledge: An automated approach to generate cases for medical case-based reasoning systems", *International Journal of Medical Informatics*, 68(1-3), 2002, 187-203.
- Agarwal, Ashwin. et al., "Commercial Landscape of Noninvasive Prenatal Testing in the United States", *Prenatal Diagnosis*, 33, 2013, 521-531.
- Alaedddini, R. et al., "Forensic implications of genetic analyses from degraded DNA—A review", *Forensic Science International: Genetics*, vol. 4, 2010, 148-157.
- Alberts, B. et al., "Chapter 20: Germ Cells and Fertilization", *Molecular Biology of the Cell*, Fourth Edition, 2002, 1127-1156.
- Alberts, B. et al., "Chapter 4: DNA and Chromosomes", *Molecular Biology of the Cell*, Fourth Edition, 2002, 191-234.
- Alkan, Can et al., "Personalized Copy Number and Segmental Duplication Maps Using Next-Generation Sequencing", *Nature Genetics*, 41, 10, 2009, 1061-1068.
- Allaire, F. R. , "Mate selection by selection index theory", *Theoretical Applied Genetics*, 57(6), 1980, 267-272.
- Allan, J. et al., "Micrococcal Nuclease Does Not Substantially Bias Nucleosome Mapping", *Journal of Molecular Biology*, vol. 417, Jan. 30, 2012, 152-164.
- Allawi, Hatim T. et al., "Thermodynamics of internal C•T Mismatches in DNA", *Nucleic Acids Research*, 26 (11), 1998, 2694-2701.
- Andras, S. C. et al., "Strategies for Signal Amplification in Nucleic Acid Detection", *Molecular Biotechnology*, vol. 19, 2001, 29-44.
- Anker, P. et al., "Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients", *Cancer and Metastasis Reviews*, vol. 18, 1999, 65-73.
- Antonarakis, S. E. et al., "Chromosome 21 and Down Syndrome: From Genomics to Pathophysiology", *Nature Reviews Genetics*, vol. 5, Oct. 2004, 725-738.
- Aoki, Yasuhiro , "Statistical and Probabilistic Bases of Forensic DNA Testing", *The Journal of the Iwate Medical Association*, 2002, vol. 54, p. 81-94.
- Ashoor, G. et al., "Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks' gestation: relation to maternal and fetal characteristics", *Ultrasound in Obstetrics and Gynecology*, vol. 41, 2013, 26-32.
- Ashoor, Ghalia et al., "Chromosome-Selective Sequencing of Maternal Plasma Cell-Free DNA for First-Trimester Detection of Trisomy 21 and Trisomy 18", *American Journal of Obstetrics & Gynecology*, 206, 2012, 322.e1-322.e5.
- Ashoor, Ghalia et al., "Fetal Fraction in Maternal Plasma Cell-Free DNA at 11-13 Weeks' Gestation: Effect of Maternal and Fetal Factors", *Fetal Diagnosis Therapy*, 2012, 1-7.
- Bada, Michael A. et al., "Computational Modeling of Structural Experimental Data", *Methods in Enzymology*, 317, 2000, 470-491.
- Bai, H. et al., "Detection and Clinical Significance of Intratumoral EGFR Mutational Heterogeneity in Chinese Patients with Advanced Non-Small Cell Lung Cancer", *PLOS One*, vol. 8, No. 2, Feb. 2013, 7 pages.
- Ballif, B. C. et al., "Detection of Low-Level Mosaicism by Array CGH in Routine Diagnostic Specimens", *American Journal of Medical Genetics Part A*, vol. 140A, 2006, 2757-2767.
- Baumont, Mark A et al., "The Bayesian Revolution in Genetics", *Nature Reviews Genetics*, 5, 2004, 251-261.
- Beck, J. et al., "Digital Droplet PCR for Rapid Quantification of Donor DNA in the Circulation of Transplant Recipients as a Potential Universal Biomarker of Graft Injury", *Clinical Chemistry*, vol. 59, No. 12, 2013, 1732-1741.
- Beer, Alan E. et al., "The Biological Basis of Passage of Fetal Cellular Material into the Maternal Circulation", *Annals New York Academy of Sciences*, 731, 1994, 21-35.
- Beerenwinkel, et al., "Methods for Optimizing Antiviral Combination Therapies", *Bioinformatics*, 19(1), 2003, i16-i25.
- Beerenwinkel, N. et al., "Geno2pheno: estimating phenotypic drug resistance from HIV-1 genotypes", *Nucleic Acids Research*, 31(13), 2003, 3850-3855.
- Benn, P. et al., "Non-Invasive Prenatal Testing for Aneuploidy: Current Status and Future Prospects", *Ultrasound Obstet Gynecol*, 42, 2013, 15-33.
- Benn, P et al., "Non-Invasive prenatal Diagnosis for Down Syndrome: the Paradigm Will Shift, but Slowly", *Ultrasound Obstet. Gynecol.*, 39, 2012, 127-130.
- Bentley, David R et al., "Accurate Whole Human Genome Sequencing Using Reversible Terminator Chemistry", *Nature*, 456, 6, 2008, 53-59.
- Bermudez, M. et al., "Single-cell sequencing and mini-sequencing for preimplantation genetic diagnosis", *Prenatal Diagnosis*, 23, 2003, 669-677.
- Beroud, C. et al., "Prenatal diagnosis of spinal muscular atrophy by genetic analysis of circulating fetal cells", *The Lancet*, vol. 361, Mar. 22, 2003, 1013-1014.
- Bevinetto, Gina , Bevinetto (5 Foods All Pregnant Women Need, American Baby, available at <http://www.parents.com/pregnancy/mybody/nutrition/5greatpregnancyfoods/>, Apr. 15, 2008), 8 pgs.
- Bianchi, D W. et al., "Fetal gender and aneuploidy detection using fetal cells maternal blood: analysis of NIFTY 1 data", *Prenat Diagn* 2002; 22, 2002, 609-615.
- Bianchi, D. W. , "Circulating Fetal DNA: Its Origin and Diagnostic Potential—A Review", *Placenta*, vol. 25, Supplemental A, May 2004, S93-S101.

(56)

References Cited

OTHER PUBLICATIONS

- Bianchi, D. W. et al., "Genome-Wide Fetal Aneuploidy Detection by Maternal Plasma DNA Sequencing", *Obstetrics & Gynecology*, vol. 119, No. 5, May 2012, 890-901.
- Bianchi, D. W., "Review: Fetal Cells in the Maternal Circulation: Feasibility for Prenatal Diagnosis", *British Journal of Haematology*, vol. 105, 1999, 574-583.
- Birch, Lyndsey et al., "Accurate and Robust Quantification of Circulating Fetal and Total DNA in Maternal Plasma from 5 to 41 Weeks of Gestation", *Clinical Chemistry*, 51(2), 2005, 312-320.
- Birkenkamp-Demtroder, K. et al., "Abstract 3653: Sequencing of plasma cfDNA from patients with locally advanced bladder cancer for surveillance and therapeutic efficacy monitoring", *Cancer Research*, vol. 78, No. 13 Supplement, Jul. 2019, 1 page.
- Bisignano, et al., "PGD and Aneuploidy Screening for 24 Chromosomes: Advantages and Disadvantages of Competing Platforms", *Reproductive BioMedicine Online*, 23, 2011, 677-685.
- Bodenreider, O., "The Unified Medical Language System (UMLS): Integrating Biomedical Terminology", *Nucleic Acids Research*, 32, (Database issue), 2004, D267-D270.
- Breithaupt, Holger, "The Future of Medicine", *EMBO Reports*, 21(61), 2001, 465-467.
- Brownie, Jannine et al., "The Elimination of Primer-Dimer Accumulation in PCR", *Nucleic Acids Research*, 25(16), 1997, 3235-3241.
- Burkova, E. E. et al., "Extremely Stable Soluble High Molecular Mass Multi-Protein Complex with DNase Activity in Human Placental Tissue", *PLOS One*, vol. 9, No. 11: e011234, Nov. 26, 2014, 26 pages.
- Burnham, P. et al., "Myriad Applications of Circulating Cell-Free DNA in Precision Organ Transplant Monitoring", *Annals of the American Thoracic Society*, vol. 14, Supplement 3, Sep. 2017, S237-S241.
- Butler, J. et al., "The Development of Reduced Size STR Amplicons as Tools for Analysis of Degraded DNA", *Journal of Forensic Sciences*, vol. 48, No. 5, 2003, 1054-1064.
- Butt, A. N. et al., "Overview of Circulating Nucleic Acids in Plasma/Serum: Update on Potential Prognostic and Diagnostic Value in Diseases Excluding Fetal Medicine and Oncology", *Ann. N.Y. Acad. Sci.*, vol. 1137, 2008, 236-242.
- Cairns, Paul et al., "Homozygous Deletions of 9p21 in Primary Human Bladder Tumors Detected by Comparative Multiplex Polymerase Chain Reaction", *Cancer Research*, 54, 1994, 1422-1424.
- Caliendo, Angela, "Multiplex PCR and Emerging Technologies for the Detection of Respiratory Pathogens", *Clinical Infectious Diseases*, 52(4), 2011, S326-S330.
- Cansar, "Hs-578-T—Copy Number Variation—Cell Line Synopsi", ICR Cancer Research UK, Retrieved on Mar. 26, 2018 from https://cansar.icr.ac.uk/cansar/cell-lines/Hs-578-T/copy_number_variation/chromosome_8/, Mar. 26, 2018, 50 pgs.
- Carnevale, Alessandra et al., "Attitudes of Mexican Geneticists Towards Prenatal Diagnosis and Selective Abortion", *American Journal of Medical Genetics*, 75, 1998, 426-431.
- Carvalho, B. et al., "Exploration, normalization, and genotype calls of high-density oligonucleotide SNP array data", *Biostatistics*, vol. 8, No. 2, 2007, 485-499.
- Casbon, J. A. et al., "A method for counting PCR template molecules with application to next-generation sequencing", *Nucleic Acids Research*, vol. 39, No. 12, Apr. 13, 2011, 1-8.
- Chakraborty, R. et al., "Paternity Exclusion by DNA Markers: Effects of Paternal Mutations", *Journal of Forensic Sciences*, vol. 41, No. 4, Jul. 1996, 671-677.
- Chan, K.C. et al., "Size Distributions of Maternal and Fetal DNA in Maternal Plasma", *Clinical Chemistry*, vol. 50, No. 1, 2004, 88-92.
- Chang, H.W. et al., "Assessment of Plasma DNA Levels, Allelic Imbalance, and CA 125 as Diagnostic Tests for Cancer", *Journal of the National Cancer Institute*, vol. 94, No. 22, Nov. 20, 2002, 1697-1703.
- Chen, E. et al., "Noninvasive Prenatal Diagnosis of Fetal Trisomy 18 and Trisomy 13 by Maternal Plasma DNA Sequencing", *PLoS ONE*, 6 (7), e21791, 2011, 7 pgs.
- Chen, X. Q. et al., "Microsatellite alterations in plasma DNA of small cell lung cancer patients", *Nature Medicine*, vol. 2, No. 9, Sep. 1996, 1033-1035.
- Chetty, Shilpa et al., "Uptake of Noninvasive Prenatal Testing (NIPT) in Women Following Positive Aneuploidy Screening", *Prenatal Diagnosis*, 33, 2013, 542-546.
- Cheung, S. W. et al., "Rapid Publication: Microarray-Based CGH Detects Chromosomal Mosaicism Not Revealed by Conventional Cytogenetics", *American Journal of Medical Genetics Part A*, vol. 143A, 2007, 1679-1686.
- Cheung, V. G. et al., "Whole genome amplification using a degenerate oligonucleotide primer allows hundreds of genotypes to be performed on less than one nanogram of genomic DNA", *Proceedings of the National Academy of Sciences, USA*, vol. 93, Dec. 1996, 14676-14679.
- Chiu, R. et al., "Non-Invasive Prenatal Assessment of Trisomy 21 by Multiplexed Maternal Plasma DNA Sequencing: Large Scale Validity Study", *BMJ*, 342, c7401, 2011, 9 pgs.
- Chiu, Rossa W. et al., "Effects of Blood-Processing Protocols on Fetal and Total DNA Quantification in Maternal Plasma", *Clinical Chemistry*, 47(9), 2001, 1607-1613.
- Chiu, Rossa W.K. et al., "Maternal Plasma DNA Analysis with Massively Parallel Sequencing by Litigation for Noninvasive Prenatal Diagnosis of Trisomy 21", *Clinical Chemistry*, 56, 3, 2010, 459-463.
- Chiu, Rossa W.K. et al., "Non-Invasive Prenatal Diagnosis by Single Molecule Counting Technologies", *Trends in Genetics*, 25 (7), 2009, 324-331.
- Chiu, Rossa W.K. et al., "Noninvasive Prenatal Diagnosis of Fetal Chromosomal Aneuploidy by Massively Parallel Genomic Sequencing of DNA in Maternal Plasma (with Supporting Information)", *PNAS*, vol. 105, No. 51, 2008, 20458-20463.
- Choi, M. et al., "Genetic diagnosis by whole exome capture and massively parallel DNA sequencing", *PNAS*, vol. 106, No. 45, Nov. 10, 2009, 19096-19101.
- Chu, T. et al., "Statistical Considerations for Digital Approaches to Non-Invasive Fetal Genotyping", *Bioinformatics (Advance Access publication)*, 26 (22), 2010, 2863-2866.
- Chu, Tianjiao et al., "Statistical Model for Whole Genome Sequencing and its Application to Minimally Invasive Diagnosis of Fetal Genetic Disease", *Bioinformatics*, 25(10), 2009, 1244-1250.
- Chu, Tianjiao. et al., "A Novel Approach Toward the Challenge of Accurately Quantifying Fetal DNA in Maternal Plasma", *Prenatal Diagnosis*, 30, 2010, 1226-1229.
- Cole, Neal W. et al., "Hyperglycemia-Induced Membrane Lipid Peroxidation and Elevated Homocysteine Levels Are Poorly Attenuated by Exogenous Folate in Embryonic Chick Brains", *Comparative Biochemistry and Physiology, Part B*, 150, 2008, 338-343.
- Colella, S. et al., "QuantiSNP: an Objectives Bayes Hidden-Markov Model to Detect and Accurately Map Copy Number Variation Using SNP Genotyping Data", *Nucleic Acids Research*, 35 (6), 2007, 2013-2025.
- Conlin, L. K. et al., "Mechanisms of mosaicism, chimerism and uniparental disomy identified by single nucleotide polymorphism array analysis", *Human Molecular Genetics*, vol. 19, No. 7, Jan. 6, 2010, 1263-1275.
- Coomes, R. C., "Abstract P4-01-02: Early detection of residual breast cancer through a robust, scalable and personalized analysis of circulating tumour DNA (ctDNA) antedates overt metastatic recurrence", *Cancer Research*, vol. 79, No. 4 Supplement, Feb. 15, 2019.
- Cossu, Gianfranco et al., "Rh D/d Genotyping by Quantitative Polymerase Chain Reaction and Capillary Zone Electrophoresis", *Electrophoresis*, 17, 1996, 1911-1915.
- Coyle, J. F. et al., "Standards for detailed clinical models as the basis for medical data exchange and decision support", *International Journal of Medical Informatics*, 69(2-3), 2003, 157-174.
- Craig, D. W. et al., "Identification of genetic variants using bar-coded multiplexed sequencing", *Nature Methods*, vol. 5, Oct. 2008, 887-893.

(56)

References Cited

OTHER PUBLICATIONS

- Cross, Jillian et al., "Resolution of trisomic mosaicism in prenatal diagnosis: estimated performance of a 50K SNP microarray", *Prenat Diagn* 2007; 27, 2007, 1197-1204.
- D'Aquila, Richard et al., "Maximizing sensitivity and specificity of PCR by pre-amplification heating", *Nucleic Acids Research*, 19(13), 1991, p. 3749.
- Daruwala, Raoul-Sam et al., "A Versatile Statistical Analysis Algorithm to Detect Genome Copy Number Variation", *PNAS*, 101(46), 2004, 16292-16297.
- Dawson, S.J. et al., "Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer", *The New England Journal of Medicine*, vol. 368, No. 13, Mar. 28, 2013, 1199-1209.
- De Bruin, E. et al., "Spatial and temporal diversity in genomic instability processes defines lung cancer evolution", *Science*, vol. 346, No. 6206, Oct. 10, 2014, 251-256.
- De Vries, et al., "Diagnostic genome profiling in mental retardation", *Am J Hum Genet*, 77, published online Aug. 30, 2005, 2005, 606-616.
- Deangelis, M. et al., "Solid-phase Reversible Immobilization for the Isolation of PCR Products", *Nucleic Acids Research*, 23 (22), 1995, 4742-4743.
- Deng, S. et al., "TNER: A Novel Background Error Suppression Method for Mutation Detection in Circulating Tumor DNA", *bioRxiv*, <http://dx.doi.org/10.1101/214379>, Nov. 5, 2017, 12 pgs.
- Deutsch, S. et al., "Detection of aneuploidies by paralogous sequence quantification", *J Med Genet*, vol. 41, 2004, 908-915.
- Devaney, S. et al., "Noninvasive Fetal Sex Determination Using Cell-Free Fetal DNA: A Systematic Review and Meta-analysis", *JAMA*, 306 (6), 2011, 627-636.
- Dhallan, et al., "Methods to Increase the Percentage of Free Fetal DNA Recovered from the Maternal Circulation", *JAMA*, 291(9), 2004, 1114-1119.
- Dhallan, Ravinder et al., "A non-invasive test for prenatal diagnosis based on fetal DNA present in maternal blood: a preliminary study", *The Lancet*, 369, 2007, 474-481.
- Dieffenbach, C W. et al., "General concepts for PCR primer design", *Genome Research. PCR methods and Applications* vol. 3, 1993, S30-S37.
- Diehl, F. et al., "Circulating mutant DNA to assess tumor dynamics", *Nature Medicine*, vol. 14, No. 9, Jul. 31, 2008, 985-990.
- Diehl, F. et al., "Detection and quantification of mutations in the plasma of patients with colorectal tumors", *PNAS*, vol. 102, No. 45, Nov. 8, 2005, 16368-16373.
- Dietmaier, W. et al., "Multiple Mutation Analyses in Single Tumor Cells with Improved Whole Genome Amplification", *American Journal of Pathology*, vol. 154, No. 1, Jan. 1999, 83-95.
- Ding, C et al., "Direct molecular haplotyping of long-range genomic DNA with M1-PCR", *PNAS* 100(13), 2003, 7449-7453.
- Dodge, Y. , "Bayes' Theorem", *The Concise Encyclopedia of Statistics*, 2008, 30-31.
- Dohm, J. et al., "Substantial Biases in Ultra-Short Read Data Sets From High-Throughput DNA Sequencing", *Nucleic Acids Research*, 36 (16), e105, 2008, 10 pgs.
- Dolganov, Gregory et al., "A Novel Method of Gene Transcript Profiling in Airway Biopsy Homogenates Reveals Increased Expression of a Na⁺-K⁺-Cl⁻-Cotransporter (NKCC1) in Asthmatic Subjects", *Genome Res.*, 11, 2001, 1473-1483.
- Donaghue, C. et al., "Detection of mosaicism for primary trisomies in prenatal samples by QF-PCR and karyotype analysis", *Prenatal Diagnosis*, vol. 25, 2005, 65-72.
- Donohoe, Gerard G et al., "Rapid Single-Tube Screening of the C282Y Hemochromatosis Mutation by Real-Time Multiplex Allele-specific PCR without Fluorescent Probes", *Clinical Chemistry*, 46, 10, 2000, 1540-1547.
- Donoso, P. et al., "Current Value of Preimplantation Genetic Aneuploidy Screening in IVF", *Human Reproduction Update*, 13(1), 2007, 15-25.
- Echeverri, et al., "Caffeine's Vascular Mechanisms of Action", *International Journal of Vascular Medicine* vol. 2010(2010), 10 pages, Aug. 25, 2010.
- Ehrlich, Mathias et al., "Noninvasive Detection of Fetal Trisomy 21 by Sequencing of DNA in Maternal Blood: A Study in a Clinical Setting", *American Journal of Obstetrics & Gynecology*, 204, 2011, 205.e1-205.e11.
- Eichler, H. , "Mild Course of Fetal Rh D Haemolytic Disease due to Maternal Alloimmunisation to Paternal HLA Class I and II Antigens", *Vox Sang*, 68, 1995, 243-247.
- Ellison, Aaron M. , "Bayesian Inference in Ecology", *Ecology Letters*, vol. 7, 2004, 509-520.
- Ellonen, P. et al., "Development of SNP Microarray for Supplementary Paternity Testing", *International Congress Series*, 1261, 2004, 12-14.
- EP06838311.6. , "European Communication and Extended European Search Report", dated Dec. 30, 2008, 8 pgs.
- EP08742125.1. , "European Communication pursuant to Article 94(3) EPC and Examination Report", dated Feb. 12, 2010, 5 pgs.
- Everitt, B. S. , "Medical Statistics From A to Z", 2003, 3 pages.
- Fan, et al., "Whole-genome molecular haplotyping of single cells", *Nature Biotechnology*, vol. 29, No. 1, Jan. 1, 2011, 51-57.
- Fan, Christina H. et al., "Non-Invasive Prenatal Measurement of the Fetal Genome", *Nature*, doi:10.1038/nature1251, 2012, 26 pgs.
- Fan, Christina H et al., "Noninvasive Diagnosis of Fetal Aneuploidy by Shotgun Sequencing DNA from Maternal Blood", *PNAS*, 105, 42, 2008, 16266-16271.
- Fan, H. C. et al., "Microfluidic digital PCR enables rapid prenatal diagnosis of fetal aneuploidy", *American Journal of Obstetrics & Gynecology*, vol. 200, May 2009, 543.e1-543.e7.
- Fan, H. Christina et al., "Sensitivity of Noninvasive Prenatal Detection of Fetal Aneuploidy from Maternal Plasma Using Shotgun Sequencing Is Limited Only by Counting Statistics", *PLoS One*, vol. 5, Issue 5 (e10439), May 3, 2010, 1-6.
- Fan, Jian-Bing et al., "Highly Parallel Genomic Assay", *Nature Reviews*, 7, 2006, 632-644.
- Fat Secret, , "5 Foods to Never Eat", "www.fatsecret.com" (printed from internet Nov. 1, 2014), 2 pages.
- Fazio, Gennaro. et al., "Identification of Rapid Markers Linked to Fusarium Crown and Root Rot Resistance (Frl) in Tomato", *Euphytica* 105, 1999, 205-210.
- Fiorentino, F. et al., "Development and Clinical Application of a Strategy for Preimplantation Genetic Diagnosis of Single Gene Disorders Combined with HLA Matching", *Molecular Human Reproduction* (Advance Access publication), 10 (6), 2004, 445-460.
- Fiorentino, F et al., "Strategies and Clinical Outcome of 250 Cycles of Preimplantation Genetic Diagnosis for Single Gene Disorders", *Human Reproduction*, 21, 3, 2006, 670-684.
- Fiorentino, Francesco et al., "Short Tandem Repeats Haplotyping of the HLA Region in Preimplantation HLA Matching", *European Journal of Human Genetics*, 13, 2005, 953-958.
- Ford, E. et al., "A method for generating highly multiplexed ChIP-seq libraries", *BMC Research Notes*, vol. 7, No. 312, May 22, 2014, 1-5.
- Forejt, et al., "Segmental trisomy of mouse chromosome 17: introducing an alternative model of Down's syndrome", *Genomics*, 4(6), 2003, 647-652.
- Forshew, et al., "Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA", *Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci. Transl. Med.* 4, 136 30 (2012), 1-12.
- Forshew, T. et al., "Supplementary Materials for Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA", *Sci. Transl. Med.*, vol. 4, May 30, 2012, 20 pgs.
- Fouquet, C. et al., "Rapid and Sensitive p53 Alteration Analysis in Biopsies from Lung Cancer Patients Using a Functional Assay and a Universal Oligonucleotide Array: A Prospective Study", *Clinical Cancer Research*, vol. 10, May 15, 2004, 3479-3489.
- Fredriksson, et al., "Multiplex amplification of all coding sequences within 10 cancer genes by Gene-Collector", *Nucleic Acids Research*, 2007, vol. 35, No. 7 e47, 1-6.

(56)

References Cited

OTHER PUBLICATIONS

- Freeman, Jennifer L. et al., "Copy Number Variation: New Insights in Genome Diversity", *Genome Research*, 16, 2006, 949-961.
- Frost, Mackenzie S et al., "Differential Effects of Chronic Pulsatile Versus Chronic Constant Maternal Hyperglycemia on Fetal Pancreatic B-Cells", *Journal of Pregnancy*, 2012 Article ID 812094, 2012, 8.
- Fu, G. K. et al., "Counting individual DNA molecules by the stochastic attachment of diverse labels", *PNAS*, vol. 108, No. 22, May 31, 2011, 9026-9031.
- Fu, G. K. et al., "Digital Encoding of Cellular mRNAs Enabling Precise and Absolute Gene Expression Measurement by Single-Molecule Counting", *Analytical Chemistry*, vol. 86, Mar. 3, 2014, 2867-2870.
- Ganshirt-Ahlert, D. et al., "Ratio of Fetal to Maternal DNA is Less Than 1 in 5000 at different Gestational Ages in Maternal Blood", *Clinical Genetics*, 38, 1990, 38-43.
- Ganshirt-Ahlert, D. et al., "Fetal DNA in Uterine Vein Blood", *Obstetrics & Gynecology*, 80 (4), 1992, 601-603.
- Ganshirt-Ahlert, Dorothee et al., "Three Cases of 45,X/46,XYnf Mosaicism", *Human Genetics*, 76, 1987, 153-156.
- Garcia-Murillas, I. et al., "Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer", *Science Translational Medicine*, vol. 7, No. 302, Aug. 26, 2015, 1-2.
- Gardina, P. et al., "Ploidy Status and Copy Number Aberrations in Primary Glioblastomas Defined by Integrated Analysis of Allelic Ratios, Signal Ratios and Loss of Heterozygosity Using 500K SNP Mapping Arrays", *BMC Genomics*, 9 (489), (doi:10.1186/1471-2164-9-489), 2008, 16 pgs.
- Geiss, G. K. et al., "Direct multiplexed measurement of gene expression with color-coded probe pairs", *Nature Biotechnology*, vol. 26, No. 3, Feb. 17, 2008, 317-325.
- Ghanta, Sujana et al., "Non-Invasive Prenatal Detection of Trisomy 21 Using Tandem Single Nucleotide Polymorphisms", *PLoS ONE*, 5 (10), 2010, 10 pgs.
- Gholami, M. et al., "A tailed PCR procedure for cost-effective, two-order multiplex sequencing of candidate genes in polyploid plants", *Plant Biotechnology Journal*, vol. 10, 2012, 635-645.
- Gielis, E. M. et al., "Plasma donor-derived cell-free DNA kinetics after kidney transplantation using a single tube multiplex PCR assay", *PLoS One*, vol. 13, No. 12, e0208207, Dec. 6, 2018, 16 pgs.
- Gjertson, David W. et al., "Assessing Probability of Paternity and the Product Rule in DNA Systems", *Genetica*, 96, 1995, 89-98.
- Greenwalt, T. et al., "The Quantification of Fetomaternal Hemorrhage by an Enzyme-Linked Antibody Test with Glutaraldehyde Fixation", *Vox Sang*, 63, 1992, 268-271.
- Grskovic, M. et al., "Validation of a Clinical-Grade Assay to Measure Donor-Derived Cell-Free DNA in Solid Organ Transplant Recipients", *The Journal of Molecular Diagnostics*, vol. 18, No. 6+Supplemental Appendix S1, Nov. 2016, 890-902.
- Guerra, J. , "Terminal Contributions for Duplex Oligonucleotide Thermodynamic Properties in the Context of Nearest Neighbor Models", *Biopolymers*, 95(3), (2010), 2011, 194-201.
- Guetta, Esther et al., "Analysis of Fetal Blood Cells in the Maternal Circulation: Challenges, Ongoing Efforts, and Potential Solutions", *Stem Cells and Development*, 13, 2004, 93-99.
- Guichoux, et al., "Current Trends in Microsatellite Genotyping", *Molecular Ecology Resources*, 11, 2011, 591-911.
- Gunderson, K. L. et al., "A genome-wide scalable SNP genotyping assay using microarray technology", *Nature Genetics*, vol. 37, No. 5, May 2005, 549-554.
- Gundry, C. N. et al., "Base-pair neutral homozygotes can be discriminated by calibrated high-resolution melting of small amplicons", *Nucleic Acids Research*, vol. 36, No. 10, Apr. 29, 2008, 3401-3408.
- Hall, M. , "Panorama Non-Invasive Prenatal Screening for Microdeletion Syndromes", Apr. 1, 2014 (Apr. 1, 2014), XP055157224, Retrieved from the Internet: URL:<http://www.panoramatest.com/sites/default/files/files/PanoramaMicrodeletionsWhite Paper-2.pdf> [retrieved on Dec. 8, 2014].
- Han, S-W et al., "Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non-Small-Cell Lung Cancer Patients Treated With Gefitinib", *Journal of Clinical Oncology*, vol. 23, No. 11, Apr. 10, 2005, 2493-2501.
- Handyside, et al., "Isothermal whole genome amplification from single and small numbers of cells: a new era for preimplantation genetic diagnosis of inherited disease", *Molecular Human Reproduction* vol. 10, No. 10 pp. 767-772, 2004.
- Hara, Eiji et al., "Subtractive eDNA cloning using oligo(dT)30-latex and PCR: isolation of eDNA clones specific to undifferentiated human embryonal carcinoma cells", *Nucleic Acids Research*, 19(25), 1991, 7097-7104.
- Hardenbol, P. , "Multiplexed Genotyping With Sequence-Tagged Molecular Inversion Probes", *Nature Biotechnology*, 21 (6), 2003, 673-678.
- Hardenbol, Paul et al., "Highly multiplexed molecular inversion probe genotyping: Over 10,000 targeted SNPs genotyped in a single tube assay", *Genome Research*, 15, 2005, 269-275.
- Harismendy, O. et al., "Method for Improving Sequence Coverage Uniformity of Targeted Genomic Intervals Amplified by LR-PCR Using Illumina GA Sequencing-By-Synthesis Technology", *Bio Techniques*, 46(3), 2009, 229-231.
- Harper, J. C. et al., "Recent Advances and Future Developments in PGD", *Prenatal Diagnosis*, 19, 1999, 1193-1199.
- Harton, G.L. et al., "Preimplantation Genetic Testing for Marfan Syndrome", *Molecular Human Reproduction*, 2 (9), 1996, 713-715.
- Hartwell, L. H. et al., "Chapter 11: The Direct Detection of Genotype Distinguishes Individual Genomes", *Genetics: From Genes to Genomes*, Second Edition, 2004, 371-414.
- Hartwell, L. H. et al., "Chapter 13: Chromosomal Rearrangements and Changes in Chromosome Number Reshape Eukaryotic Genomes", *Genetics: From Genes to Genomes*, Second Edition, 2004, 441-486.
- Hattori, M. et al., "The DNA sequence of human chromosome 21", *Nature*, vol. 405, May 18, 2000, 311-319.
- Hawkins, T. et al., "Whole genome amplification—applications and advances", *Current Opinion in Biotechnology*, 13, 2002, 65-67.
- Hayden, et al., "Multiplex-Ready PCR: A new method for multiplexed SSR AND SNP genotyping", *BMC Genomics* 2008, 9(80), 1-12.
- He, Qz et al., "A method for improving the accuracy of non-invasive prenatal screening by cell-free foetal DNA size selection", *British Journal of Biomedical science*, vol. 75, No. 3, Jul. 2018, 133-138.
- Hellani, A. et al., "Clinical Application of Multiple Displacement Amplification in Preimplantation Genetic Diagnosis", *Reproductive BioMedicine Online*, 10 (3), 2005, 376-380.
- Hellani, Ali et al., "Multiple displacement amplification on single cell and possible PGD applications", *Molecular Human Reproduction*, 10(11), 2004, 847-852.
- Hojsgaard, S. et al., "BIFROST—Block recursive models induced from relevant knowledge, observations, and statistical techniques", *Computational Statistics & Data Analysis*, 19(2), 1995, 155-175.
- Hollas, B. et al., "A stochastic approach to count RNA molecules using DNA sequencing methods", *Lecture Notes in Computer Science*, vol. 2812, 2003, 55-62.
- Holley, et al., "Multiplex Manager 1.0: a Cross-Platform Computer Program that Plans and Optimizes Multiplex PCR", *BioTechniques* 46:511-517 (Jun. 2009), 511-517.
- Hollox, E. et al., "Extensive Normal Copy Number Variation of a β -Defensin Antimicrobial-Gene Cluster", *Am. J. Hum. Genet.*, 73, 2003, 591-600.
- Homer, et al., "Resolving Individuals Contributing Trace Amounts of DNA to Highly Complex Mixtures Using High-Density SNP Genotyping Microarrays", *PLoS Genetics*, 4(8), 2008, 9 pgs.
- Hoogendoorn, Bastiaan et al., "Genotyping Single Nucleotide Polymorphisms by Primer Extension and High Performance Liquid Chromatography", *Hum Genet*, 104, 1999, 89-93.
- Hornak, M. et al., "Aneuploidy Detection in Pigs Using Comparative Genomic Hybridization: From the Oocytes to Blastocysts", *PLoS One*, vol. 7, No. 1, Jan. 2012, 6 pages.
- Hospital, F. et al., "A General Algorithm to Compute Multilocus Genotype Frequencies Under Various Mating Systems" vol. 12, No. 6, Jan. 1, 1996 (Jan. 1, 1996), pp. 455-462.